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TIIVISTELMÄ 
 
Tutkimuksen tausta ja tavoitteet: Mitokondrion elektroninsiirtoketjun häiriöt aiheuttavat 
sairauksia, joita kutsutaan yleisesti mitokondriosairauksiksi. Tällä hetkellä näihin sairauksiin ei ole 
olemassa parannuskeinoa. Tutkimuksessa mitokondriosairauksien molekulaarista patologiaa 
mallinettiin Drosophila melanogasterissa hiljentämällä hermosoluspesifisti sytokromi-c-oksidaasi -
geeni. Tutkimuksen tavoitteena oli karakterisoida hermosoluspesifin COX-KD kärpäsen fenotyyppi 
ja kokeilla, voidaanko vaihtoehtoisen oksidaasin avulla parantaa vahingollisen fenotyypin omaavat 
kärpäset.  
 
Tutkimusmenetelmät: Sytokromi-c-oksidaasin alayksiköiden geenien hiljentämiseen käytettiin 
GAL4-UAS -systeemiä. Kahta eri RNAi-konstruktia ekspressoitiin hermosoluspesifisti kolmella eri 
GAL4 geeniajurilla. Sekä geenien hiljentymisen että vaihtoehtoisen oksidaasin ekspression 
varmistamiseksi, kärpäsen hermo- ja lihaskudosleikkeitä värjättiin fluerosoivilla vasta-aineilla. 
COX-KD kärpästen fenotyyppi määritettiin elinkyvyn (lethality) ja elinkyvyn asteittaisen 
heikkenemisen (survival) perusteella. Samat kokeet toistettiin kärpäsillä, jotka ekspressoivat joko 
vaihtoehtoista oksidaasia tai Ndi1:tä COX-KD ohella. Lisäksi elav-GAL4 geeniajurien ekspressio 
kärpäsen eri kehitysasteissa ja eri kudoksissa määritettiin GFP:n avulla. 
 
Tutkimustulokset: Hermosoluspesifi COX-KD aiheutti Drosophila melanogasterissa erilaisia 
fenotyyppejä, muun muassa osittaista tai täydellistä letaalisuutta, liikuntakyvyn puutteita, sekä 
elinkyvyn heikkenemistä. Fenotyypit olivat voimakkaampia uros kärpäsissä, sekä kärpäsissä, joissa 
knockdown kohdistui COX alayksikköön IV. Vaihtoehtoisen oksidaasin ekspressio pystyi osittain 
tai kokonaan parantamaan vahingolliset fenotyypit. Yllättäen Ndi1:n yhtäaikainen ekspressio COX-
KD kanssa aiheutti vakavamman fenotyypin kuin pelkkä COX-KD. Tutkimuksessa huomattin 
myös, että vaihtoehtoista oksidaasia ekspressoitiin lihaskudoksessa. Tarkempi tutkimus osoitti, että 
elav-GAL4 ajurit ekspressoivat UAS-transgeenejä myös keskiruumiin lihaksissa kotelovaiheessa 
sekä aikuisissa kärpäsissä. 
 
Johtopäätökset: Uroskärpästen voimakkaamat fenotyypit aiheutuivat todennäköisesti X-
kromosomaalisten geenien ekspressiotasojen kompensaatiosta. COX alayksikön IV hiljennyksen 
aiheuttama fenotyyppi kuvastaa hyvin alayksikön IV tehtävää COX-synteesin aikaisessa vaiheessa. 
Voimakkaamman fenotyypin takia voidaan olettaa, että alayksikön IV hiljentäminen johtaa 
vakavampaan sytokromi-c-oksidaasin puutokseen kuin alayksikön Vb hiljentäminen. 
Vaihtoehtoisen oksidaasin parantava vaikutus perustuu sen kykyyn palauttaa protonien pumppaus 
kompleksi I:n läpi, aiheuttaen ATP-tuoton nousun tasolle, joka sallii olennaiset tapahtumat soluissa. 
Ndi1 puolestaan vähentää edelleen protonien pumppausta kompleksi I:n läpi, saaden aikaan 
päinvastaisen vaikutuksen. Tämän ja edellisten tutkimusten perusteella vaihtoehtoisella oksidaasilla 
on potentiaalia lääkinnälliseksi molekyyliksi. 
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ABSTRACT 
 
Background and aims: Defects in mitochondrial respiratory chain produce diseases commonly 
referred as mitochondrial diseases. Mitochondrial diseases most often affect tissues that have high 
energy demands, particularly muscle and nervous system, and they are characterized by a plethora 
of symptoms. In this study, pathological effects of mitochondrial diseases were simulated in 
Drosophila melanogaster by neural specific cytochrome c oxidase knockdown. The aims of this 
research were to characterize the phenotype of neural specific COX knockdown in flies and test 
whether the alternative oxidase (AOX) can rescue the deleterious phenotypes. 
 
Materials and methods: Two UAS-RNAi constructs were used to knockdown COX subunits IV 
and Vb. RNAi was expressed in neurons by three neuronal GAL4 drivers. To verify COX 
knockdown in nervous system, sections of paraffin embedded fly muscle and brain were stained 
with  fluorescent  antibodies.  The  expression  of  AOX was  also  confirmed using  the  same method.  
The phenotype of neuronal COX-KD flies was characterized by i) viability of the flies (lethality 
assay) and ii) degenerative loss of viability after eclosion (survival assay). The same experiments 
were conducted on flies that were coexpressing AOX or Ndi1, along with COX knockdown. 
Additionally,  the  expression  pattern  of  two  elav-GAL4  drivers  was  determined  with  GFP  in  
different developmental stages in different tissues. 
 
Results: Neural specific COX-KD using elav-GAL4 drivers presented variable phenotypes, 
including partial and full lethality, locomotor defects and reduction in viability. The phenotypes 
were stronger in COX IV-KD flies compared to COX Vb-KD flies and also in males compared to 
females.  AOX  expression  was  able  to  partially  or  fully  rescue  the  deleterious  phenotypes  due  to  
COX-KD. Surprisingly,  Ndi1 expression made the phenotypes even worse.  AOX was found to be 
expressed in the thoracic muscles of flies. Closer inspection of the expression pattern of elav-GAL4 
drivers revealed that both of them drive the expression of UAS transgenes also in thoracic muscles 
at pupal and adult stages. 
 
Conclusions: Dosage compensation of X-chromosomal genes can explain the stronger phenotype 
in male flies. This is true particularly in the case of elav(X)-GAL4. The stronger phenotype in COX 
IV-KD flies reflects the role of subunit IV in early stages of COX biogenesis. Therefore COX IV-
KD is expected to lead to more severe COX dysfunction than COX Vb-KD, which is used in later 
stage of COX synthesis. AOX was able to fully or partially rescue deleterious phenotypes, which is 
attributable  to  its  ability  to  restore  proton  flow through complex  I  of  the  respiratory  chain.  Thus,  
ATP production is restored to a level that allows vital cellular functions to operate. Ndi1 expression 
seems to have the opposite effect. Therefore the level of ATP is expected to be further decreased. 
This and previous studies show that AOX has true potential to be a therapeutic agent for OXPHOS 
dysfunction.
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AOX = alternative oxidase 
ATP = adenosine triphosphate 
COX = cytochrome c oxidase 
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mtDNA = mitochondrial DNA 
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1.  INTRODUCTION 
 
Mitochondrial  diseases  are  a  diverse  group of  disorders  that  can  affect  any  tissue  in  any  stage  of  
development and growth. Mitochondrial diseases usually refer to defects of the mitochondrial 
respiratory chain (DiMauro, 2004). The commonest cause of respiratory chain defect is cytochrome 
c oxidase deficiency (Schapira, 2006). COX is the terminal enzyme of the respiratory chain and it 
links the transfer of electrons to proton pumping through the mitochondrial membrane. Currently 
there is no cure for mitochondrial diseases. 
 
Mitochondrial diseases have been modelled and studied using the fruit fly Drosophila 
melanogaster. Most notably, the knowledge of the full genome and its correspondence to human 
genome, in addition to several well-established genetical tools, makes Drosophila a good model 
animal for studying diseases (Jacobs et  al, 2004) . COX deficiencies have also been previously 
modelled in D. melanogaster by knocking down Surf1, a protein involved in COX synthesis 
(Fernandez-Ayala et  al, 2009), and COX structural subunits tissue specifically, leading to various 
phenotypes (Kemppainen et al, unpublished). Additionally, affects of COX deficiencies have been 
modelled in mice (Diaz et  al, 2006; Li et  al, 2007), nematodes (Suthammarak et  al, 2009)  and 
human cells (Antonicka et al, 2003). 
 
A possible therapeutic agent for COX deficiencies has emerged through studies of respiratory chain 
complexes in plants and fungi. These organisms possess alternative respiratory chain enzymes 
capable of bypassing some of the generic respiratory chain complexes of the mitochondrial 
OXPHOS system. The alternative oxidase (AOX) can transfer electrons directly from ubiquinone to 
molecular oxygen, thus bypassing complexes III and IV (Rustin and Jacobs, 2009). After its first 
discovery in plants and fungi, AOX has also been found in certain lower groups of animals, e.g. in 
ascidians (McDonald et al, 2009) . The therapeutic potential of AOX is based its ability to bypass 
COX. In COX-deficient patients, the respiratory chain is partially blocked and proton pumping and 
subsequent ATP production are therefore diminished. If AOX is present, it theoretically will restore 
electron flow in the first part of the respiratory chain, allowing proton pumping through complex I 
and partially restoring ATP production (Rustin and Jacobs, 2009). 
 
To  test  the  effect  of  AOX  in  COX  deficient  cells,  AOX  has  been  designed  to  be  expressed  in  
various disease models, including Drosophila (Fernandez-Ayala et al, 2009), human cells (Hakkaart 
et al, 2006)  and lately also in mouse (El-Khoury et  al, 2013). It was shown in these models that 
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AOX is imported into mitochondria and associated with the inner mitochondrial membrane. It 
remains inactive in the membrane until the cytochrome component of the respiratory chain becomes 
blocked. In previous experiments, AOX has been able to restore electron flow in the respiratory 
chain in human fibroblasts depleted of Cox15 (Dassa et al, 2009b)  and rescue Parkinson’s disease 
phenotypes and dopaminergic cell loss in Drosophila (Fernandez-Ayala et  al, 2009; Humphrey et 
al, 2012). 
 
In a previous study by Kemppainen et al (unpublished), various COX subunits were knocked down 
in different tissues with RNA interference utilizing the GAL4-UAS system. In the study, neuronal 
knockdown of subunits COX Vb and COX VIb did not produce any observable phenotypes. It 
seemed puzzling, why COX deficiency in a tissue with high energy demand would not have any 
effect. To tackle these questions, the study presented here was performed. The first aim of this study 
was to characterize the phenotype(s) of neural specific COX knockdown in Drosophila 
melanogaster. The second aim was to test whether AOX can rescue any resulting deleterious 
phenotypes. COX knockdown was produced by driving the expression of UAS-RNAi constructs 
against COX subunits IV and Vb with three different neuronal GAL4 drivers. The phenotypes were 
characterized using lethality and survival assays, which are used to determine the effect of 
knockdown on survival through development and loss of viability during a two-week testing period 
following eclosion, respectively. Paraffin sections of fly brain and muscle were stained with 
fluorescent antibodies in order to evaluate the efficiency and tissue specificity of COX knockdown. 
 
This study provides insights into the pathology of COX deficiencies and also gives information on 
how AOX is able to alleviate symptoms caused by COX deficiency. With the help of this new 
information, AOX can be used in future as a therapeutic tool for respiratory chain disorders. 
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2. REVIEW OF THE LITERATURE 
 
2.1 Mitochondria 
 
Mitochondria are organelles found in all eukaryotes, including plants, algae, animals, fungi and 
protozoa. They are responsible for most of the ATP production in cells, utilizing the respiratory 
chain and oxidative phosphorylation for this purpose. Mitochondria are the place for many other 
metabolic functions as well, for example the citric acid cycle, part of fatty acid metabolism, amino 
acid metabolism and many other redox reactions. Mitochondria have also other function not related 
to primary metabolism: steroid hormone synthesis, apoptosis and generation of heat, among others 
(Alberts et  al, 2008; Nelson and Cox, 2008). Mitochondria are believed to have originated in 
evolution through endosymbiosis between an ancient Į-proteobacterium and an early eukaryote cell 
that first happened more than 1.5 billion years ago (Dyall et al, 2004). The endosymbiosis theory is 
strongly supported by the fact that mitochondria harbour their own genome and a protein synthesis 
machinery that resembles more the bacterial than the eukaryotic cytosolic translation machinery 
(Alberts et  al, 2008). Mitochondria are found in all tissues of the human body, and their density 
reflects the energy need of that particular tissue. Therefore, tissues with high energy need, 
especially neurons, as well as cardiac and skeletal muscle cells, have a higher density of 
mitochondria (Schapira, 2006). 
 
2.1.1 Organization and structure 
 
Mitochondria were initially thought of as static organelles, but it is now known that they exist in a 
dynamic state, in which mitochondria are constantly undergoing fission and fusion (Chan, 2006). 
The continuously fusing and dividing mitochondria form a mitochondrial network inside the cell 
(Schapira, 2006). This network is often associated with microtubules, which determines 
mitochondrial distribution and spacing in different cell-types and tissues depending on their energy 
requirements (Alberts et al, 2008).  
 
Mitochondria are bounded by a double phospholipid membrane, which enclose the intermembrane 
space between them and the matrix inside the inner mitochondrial membrane (IMM). The outer 
mitochondrial membrane (OMM) is permeable to small molecules whereas the IMM is 
impermeable to ions and small molecules alike. Thus the matrix harbours a highly specific content 
of proteins and other molecules and it is the site of metabolic reactions happening inside 
mitochondria. The inner mitochondrial membrane is invaginated so that it forms a series of cristae 
or tubes, protruding into the matrix. Embedded in the IMM are also the enzymes involved in 
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oxidative phosphorylation and ATP production (Alberts et  al, 2008). Mitochondria are heavily 
dependent on nuclear-encoded proteins and enzymes related to transcription, translation and DNA 
replication and repair, even though they have their own genome and translation machinery 
(Schapira, 2006). The proteins produced in the cytosol have to be transported into mitochondria to 
their site of action. Therefore these proteins contain mitochondrial localization signals that reside 
either in the N-terminal end (most proteins targeted to the matrix and IMM), or internally to the 
polypeptide (some proteins targeted to IMM). Both mitochondrial membranes have specific protein 
translocases, designated as the translocase of the outer membrane (TOM) and translocase of inner 
membrane (TIM), which transport proteins from the cytosol to the intermembrane space and to the 
matrix, respectively (Neupert, 1997).  
 
2.1.2 Mitochondrial genetics 
 
2.1.2.1 Genome organization, replication, transcription and translation 
 
Mitochondria possess their own genome, which is organized as a double stranded, circular DNA 
molecule. The genome organization resembles more that of the bacterial than the eukaryotic 
chromosome, due to the fact that it is not associated with histones. Mitochondrial genomes come in 
various sizes. The human mitochondrial genome is approximately 16.6 kb long, whereas that of 
Drosophila melanogaster is roughly 19.5 kb (Lewis et  al, 1995; Alberts et  al, 2008). The two 
strands of the mammalian mitochondrial genome are different in their G+T base composition, 
which makes them separate in caesium chloride density-gradient centrifugation into light and heavy 
strands. There are many copies of the genome in single mitochondria, and the copy number varies 
between different types of cells (Taanman, 1999). However, both high and low mitochondrial DNA 
(mtDNA) copy numbers seem to be associated with elevated risk of developing cancer 
(Thyagarajan et al, 2013; Yu, 2011). 
 
Mitochondrial DNA encodes 22 tRNAs, 2 rRNAs and 13 polypeptides. All of the 13 polypeptides 
are subunits of the respiratory chain or OXPHOS enzyme complexes. The genes are encoded on 
both the light and heavy strands. The genes in human mtDNA are very densely packed, meaning 
there  are  no  introns  and  only  two  major  non-coding  stretches  that  contain  regulatory  sites  
(Taanman, 1999; Fernandez-Silva et al, 2003). The Drosophila mitochondrial genome harbours the 
same genes as vertebrates, and they also lack introns. The only distinctive feature of the Drosophila 
mtDNA is the organization and distribution of the genes in the two strands (Berthier et al, 1986). In 
mammals, the major non-coding region in mtDNA is called the displacement loop, or D-loop, 
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because of its unique triple-stranded structure (Clayton, 2000). The D-loop is adjacent to the origin 
of  replication  of  the  heavy  strand  and  the  promoter  sites  LSP  and  HSP  for  the  light-  and  heavy-
strands, respectively. The major origin of light-strand replication is located in the shorter non-
coding region (only ~30 nucleotides long), situated inside a tRNA cluster (Fernandez-Silva et  al, 
2003). MtDNA is replicated independently of the state of the cell, even in non-dividing cells 
(Schapira, 2006). Mitochondria possess their own DNA polymerase, polymerase Ȗ that also has a 
proofreading activity for maintaining sequence fidelity. The mtDNA replication machinery also 
includes a mitochondrial helicase, Twinkle, that unwinds double-stranded DNA ahead of the 
polymerase, as well as a mitochondrial single-strand binding protein (mtSSB) that protects single-
stranded DNA (Fernandez-Silva et al, 2003). The way in which mtDNA is replicated is still under 
debate. Currently there are three models for mtDNA replication: the strand displacement model, the 
strand-coupled model and RNA incorporated throughout the lagging strand (RITOLS) model 
(Kasiviswanathan et al, 2012).  
 
As previously mentioned, transcription of mtDNA also initiates from a region adjacent to the D-
loop, which contains the promoter sites for both light- and heavy-strand transcription. In fact, there 
are three initiation sites for transcription because heavy-strand transcription can start from two 
alternative locations designated as H1 and H2. The gene content of the primary transcript depends on 
the  heavy  strand  initiation  point.  If  transcription  starts  from  H1, the primary transcript includes 
genes  for  the  two  rRNAs  and  two  tRNAs.  If  it  starts  at  H2, one polycistronic primary transcript 
covering almost the whole heavy strand is formed, including genes for the 12 polypeptides encoded 
in the heavy strand and 14 tRNAs. Transcription initiation from the light strand promoter yields one 
polycistronic transcript, including 8 tRNAs and the ND6 mRNA (Fernandez-Silva et al, 2003). The 
mitochondrial transcription machinery includes the mitochondrial RNA polymerase and 
transcription  factors  mtTFA  and  TFB2M,  which  take  part  in  initiation,  and  MTERF,  which  
participates in termination of transcription (Taanman, 1999). The polycistronic primary transcripts 
are  cut  at  both  ends  of  the  tRNA  genes  that  flank  the  rRNAs  and  the  mRNAs  by  various  
endonucleases, in order to produce individual rRNAs and mRNAs. These transcripts are then 
further processed enzymatically (Fernandez-Silva et  al, 2003). The matured mitochondrial mRNA 
transcripts bear a 3´-poly A-tail like nuclear transcripts, but they lack a 5´-cap structure (Alberts et 
al, 2008). 
 
Mitochondrial ribosomes, or mitoribosomes, are composed of two mitochondrial rRNAs, 12S and 
16S, and around 81 mitoribosomal proteins. The mitoribosomes differ from their cytosolic 
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counterparts and also from bacterial ribosomes in having significantly less rRNA. Mitochondrial 
translation includes initiation, elongation and termination steps that are effected by specific 
translation factors (e.g. mtIF2 and mtIF3 for initiation, mtEFTu and mtEFTs for elongation and 
mtRF1 and mtRRF for termination). Mitochondria use a genetic code that differs from the universal 
one in several aspects (e.g. UGA is a universal termination codon, whereas in mitochondria it codes 
for tryptophan). The mitochondrial code also differs between mammals and Drosophila. In 
addition, mitochondria use a simplified decoding system that allows them to synthesise the 13 
polypeptides by using only 22 tRNAs. Mammalian mitochondria use only a single tRNAMet for both 
initiation and elongation events (Smits et al, 2010). 
 
2.1.2.2 Inheritance and evolution 
 
Mammalian mtDNA is inherited maternally (Larsson and Clayton, 1995). The sperm also donate 
some mtDNA to the fertilized ovum, but it is directed for degradation before further development 
(Schapira, 2006). There are many thousands of copies of the mitochondrial genome in each cell, a 
state of which is called polyplasmy (Smeitink et al, 2001). Usually, all the mitochondrial genomes 
are identical in sequence (homoplasmy), but when somatic mutations start to accumulate, e.g. with 
aging, wild-type and mutant mtDNA molecules start to coexist (heteroplasmy) (Schapira, 2006). 
Upon cell division, the heteroplasmic mtDNA mutations segregate randomly into daughter cells, 
which can lead to one tissue or one cell within a tissue having a higher proportion of mutated 
mtDNA. If the mutation is pathological, it usually requires a minimum threshold level of mutated 
mtDNAs before a phenotype can manifest (see section 2.4.1). The minimum threshold level of 
mutant mtDNA depends on the mutation and the tissue being affected (Falkenberg et al, 2007). In 
animals the mutation rate in the mitochondrial genome over evolutionary time is at least 10 times 
higher than in the nuclear genome (Brown et al, 1979). This high mutation rate has been suspected 
to be due to insufficient means of repairing damaged DNA and the close physical proximity to 
damaging reactive oxygen species (ROS) inside the mitochondrial matrix (Shadel and Clayton, 
1997), although this is debated. Humans have accumulated neutral mitochondrial mutations after 
the emergence of our species and they have manifest as a series of different DNA sequence 
polymorphisms. A specific set of polymorphisms in a population is called a mitochondrial 
haplotype. Using these haplotypes, it has been possible to trace back maternal lineages all the way 
to a common maternal ancestor, and determine the migration routes used when humans first left 
Africa (Wallace et al, 1999). 
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2.1.3 The respiratory chain and oxidative phosphorylation (OXPHOS) 
 
Mitochondria are responsible for a number of metabolic functions, the most significant being the 
production of chemical energy for the cell, in the form of ATP. The end products of glycolysis and 
fatty acid breakdown are further oxidised in the TCA cycle, which produces reduced electron 
carrier molecules (NADH and FADH2). These molecules then release their electrons to the 
respiratory chain complexes, returning to their oxidised state and back to the TCA cycle, enabling 
further fuel molecule oxidisation. The electrons are passed from one respiratory chain complex to 
the next, providing the energy that is later used for oxidative phosphorylation (Nelson and Cox, 
2008). 
 
The respiratory chain encompasses multisubunit protein complexes I-IV, embedded in the inner 
mitochondrial membrane, complex V, which is the ATP synthase, and two electron carrier 
molecules: ubiquinone (coenzyme Q) inside the IMM and cytochrome c in the intermembrane space 
(Nelson and Cox, 2008). Complex I (NADH dehydrogenase) and complex II (succinate 
dehydrogenase) transfer their electrons to ubiquinone, which is reduced to ubiquinol. Ubiquinol 
transfers electrons on to complex III (cytochrome c reductase) and returns to its oxidised state. 
Complex III then transfers electrons in the intermembrane space to cytohrome c, which then 
diffuses to interact with complex IV (cytochrome c oxidase, COX), which finally transfers electrons 
from cytochrome c to molecular oxygen (Boekema and Braun, 2007). During electron transfer, 
complexes I, III and IV pump protons from the mitochondrial matrix to the intermembrane space. 
This proton pumping action stores the energy released from the electrons as an electrochemical 
gradient over the inner mitochondrial membrane. This results in the intermembrane space having a 
higher proton concentration than the matrix. The IMM thus has an electrochemical potential, 
utilizing opposing electrical charges (positive outside, negative inside) (Nelson and Cox, 2008). 
This electrochemical gradient is used as an energy source of complex V (ATP synthase) to produce 
ATP from ADP and inorganic phosphate. The ATP synthase is of the F1Fo type (Smeitink et  al, 
2001). The protons flow through the c subunits of the membrane bound section (Fo) of ATP 
synthase, making it rotate. The rotary movement of the c subunits is transferred to the Ȗ subunit of 
the section protruding the matrix side (F1).  The  Ȗ subunit  is  a  shaft,  which  is  in  contact  with  the  
catalytic ȕ subunits. There are three ȕ subunits, each either binding strongly to ATP, ADP + Pi or 
nothing, depending on the orientation of the Ȗ subunit (Nelson and Cox, 2008). This way the 
proton-motive force generates most of the ATP needed for various purposes (Alberts et al, 2008). 
Finally, ATP needs to be transported outside of mitochondria to places in the cell where it will be 
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utilised. To accomplish this task, the inner mitochondrial membrane is equipped with an adenine 
nucleotide translocator that transfers ATP from matrix to cytosol in exchange for ADP (Smeitink et 
al, 2001). An illustration of the respiratory chain structure and function is presented in Figure 2.1. 
 
The respiratory chain was first considered to exist in a fluid state, where all the complexes would 
diffuse freely in the IMM and oxidative phosphorylation would occur only on random collisions 
(Nelson and Cox, 2008). Later it was shown first in bacteria and then also in yeast and mammals 
that the respiratory complexes are associated in various stoichiometric supercomplexes, or 
“respirasomes” (Schagger and Pfeiffer, 2000). These findings support a solid-state model, in which 
the respiratory chain complexes are organised so that substrates are channelled straight from one 
complex to another. Different types of supercomplexes are believed to be present in mammalian 
mitochondria, most likely of type I1III2 and I1III2IV1 (Schafer et al, 2006; Acín-Pérez et al, 2008). 
The larger supercomplex is more abundant and also has higher activity and stability than the smaller 
one (Vonck and Schaefer, 2009). The amount of complex IV associated with the respirasome is still 
unclear: supercomplexes with one, two, four and up to six units of complex IV have been detected 
(Schagger and Pfeiffer, 2000; Acín-Pérez et al, 2008). 
 
 
 
 
 
Figure 2.1. The mitochondrial oxidative phosphorylation (OXPHOS) system. Electrons from carbohydrate and 
other nutrient oxidation reactions are transferred from NADH and FADH (succinateÆfumarate reaction) through 
complex I (cI, NADH dehydrogenase), complex II (cII, succinate dehydrogenase), small electron carrier molecule 
ubiquinone (CoQ), complex III (cIII, cytochrome c reductase), cytochrome c (Cyt c) and complex IV (cIV, 
cytohrome  c oxidase) to molecular oxygen, which is reduced to water. Concomitantly with the electron transfer, 
complexes I, III and IV pump protons from the matrix side to the intermembrane space (IMS) and the consequent 
proton gradient is utilized by complex V (cV, ATP synthase) to form ATP from ADP and inorganic phosphate.  
Diagram modified from Smeitink et al, 2001. 
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2.2 Cytochrome c oxidase 
 
2.2.1 Structure and biogenesis 
 
Cytochrome c oxidase is the final complex of the mitochondrial respiratory chain. It is a large 
protein complex, composed of 13 subunits (in mammals), some of which are encoded in each of the 
two cellular genomes, nuclear and mitochondrial (Khalimonchuk and Rödel, 2005). The 
nomenclature of COX subunits depends on the organism and in this section the mammalian 
nomenclature is used, because most of the studies presented here have been carried out on the 
mammalian enzyme (Fontanesi et  al, 2008). The three dimensional structure of the mammalian 
enzyme was solved by Tsukihara et al (1996), using X-ray crystallography. The catalytically active 
core subunits (Cox1, Cox2 and Cox3) are encoded by the mitochondrial genome. The bacterial 
enzyme  is  composed  of  only  these  three  subunits  and  they  share  sequence  homology  with  the  
mitochondrially encoded subunits. The 10 other subunits of the mammalian COX are encoded in 
the nuclear genome, translated in the cytosol and imported into mitochondria for assembly into 
complex IV (Stiburek et al, 2006). 
 
2.2.1.1 Mitochondrially encoded subunits 
 
Cox1 is the largest of all COX subunits and it is anchored tightly into the IMM with 12 
transmembrane helices. Cox1 also coordinates the electron transfer centres and proton pumping 
channels (D- and K-channels) (see section 2.2.2) (Stiburek et  al, 2006). The electron transfer 
centres are unique for COX because they fuse a heme group and copper atom. In Cox1 there are 
two catalytic centres: heme a and binuclear heme a3-CuB centre (Fontanesi et al, 2008). Cox2 is the 
smallest  of  the  core  subunits  and  it  is  also  anchored  to  the  IMM  via  transmembrane  Į-helical  
hairpin. The C-terminal head of Cox2, composed of a 10 stranded ȕ-barrel, projects into the 
intermembrane space and contains the CuA-centre and cytochrome c docking site. The last core 
subunit, Cox3, is very hydrophobic and it is anchored to the IMM with 7 transmembrane helices 
(Stiburek et al, 2006). Cox3 does not have prosthetic groups, but it seems to accomplish the rapid 
proton flow through the D-channel of Cox1 (Hosler, 2004). 
 
2.2.1.2 Nuclear-coded subunits 
 
The remaining ten nuclear-coded mammalian subunits of COX are required for synthesis and 
stability of the enzyme. They are also thought to regulate the activity of the COX complex. Most of 
the nuclear subunits are also transmembrane proteins, except for subunits Cox5a and Cox5b, which 
are located on the matrix side, and subunit Cox6b, which associates with the complex in the 
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intermembrane space. Some of the nuclear subunits have tissue-specific isoforms (usually 
heart/muscle or liver specific isoforms), including Cox4, Cox6a, Cox6b, Cox7a and Cox8 
(Fornuskova et al, 2010). Subunit 5b is known to be in contact with both Cox1 and Cox2 from the 
matrix side. The subunit includes a zinc binding site, but the significance of this motif is not known. 
It  has  also  been  noticed  that  the  subunit  5b  content  of  different  tissues  can  vary,  even  within  
different compartments of one specific tissue. Usually tissues with high energy demand have higher 
Cox5b content (Galati et  al, 2009). COX subunit 4 is the largest of the nuclear encoded subunits, 
and it has tissue-specific isoforms encoded by separate genes (Fornuskova et  al, 2010). Cox4 
mediates  allosteric  inhibition  of  the  complex  by  ATP,  which  binds  to  the  matrix  portion  of  the  
subunit (Arnold and Kadenbach, 1997).  
 
2.2.1.3 Biogenesis of cytochrome c oxidase 
 
Before the assembly of COX can start, the accessory groups have to be inserted into core subunits 
and nuclear subunits have to be imported to the site of enzyme formation (Stiburek et al, 2006). Not 
all of the protein factors or intermediate steps in COX biogenesis are currently known, but there has 
been a lot of research on the subject in recent years. Although more auxiliary proteins are being 
identified, the specific functions of only a few are known (Soto et al, 2012).  There are a number of 
factors required for the formation of heme and copper centres in Cox1 and Cox2. The heme a rings 
are synthesised sequentially from heme b rings by a series of enzymes, including Cox10 and Cox15 
(Khalimonchuk and Rödel, 2005). They are likely inserted into the Cox1 subunit early in COX 
biogenesis  before  addition  of  other  subunits,  and  the  insertion  seems  to  be  assisted  by  the  COX  
biogenesis regulator protein Surf1 (Ylikallio and Suomalainen, 2012). Cox17 and Cox19 are small 
hydrophilic proteins that function upstream in the pathway that inserts Cu-atoms to COX. The 
downstream copper-binding proteins associated with copper delivery to CuA centre of Cox2 are 
Sco1 and Sco2. The corresponding copper binding protein delivering copper to CuB of Cox1 is 
Cox11 (Stiburek et al, 2006). 
 
In the initial stages of COX assembly, Cox1 becomes associated with proteins that are not present 
in the mature COX, constituting the first subcomplex intermediate (S1). After incorporating Cox1 
into IMM, Cox1 associates with Cox4/Cox5a heterodimer, forming the subcomplex intermediate 
S2. Cox2 then joins this subcomplex. Cox2 association is a prerequisite for Cox3 association 
(Stiburek et  al, 2006), which is accompanied by the incorporation of many nuclear subunits, 
including Cox5b, Cox6c, Cox7b, Cox7c and Cox8 (intermediate S3). A recent study by Fornuskova 
et al (2010) suggested that in the late stage of COX assembly, subunits Cox7a and Cox6b are added 
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to intermediate S3 prior to the last subunit Cox6a, in two separate steps (producing the complete 13-
subunit enzyme, denoted as S4). The final, mature form of COX is achieved after some 
modifications (CuB centre coordinating amino acids are linked) and respiratory supercomplex 
formation (Khalimonchuk and Rödel. 2005). The structure of the respiratory supercomplexes was 
discussed in section 2.1.3. The COX biogenesis pathway is depicted in Figure 2.2. 
 
 
 
 
2.2.2 Modes of action: Transmission of electrons and proton translocation 
 
The electron transfer reactions and proton translocation have been studied in great detail. This has 
revealed that the reduction of oxygen to water actually happens in two phases: the reductive and 
oxidative phase (Yoshikawa et al, 2011; Yoshikawa et al, 2012). The reductive phase is composed 
of the electron transfer reactions from the metallic centres to molecular oxygen. The oxidative 
phase consists of the subsequent water formation and proton translocation (Stiburek et al, 2006). 
 
In the reductive phase, electrons are transferred to the heme a3-CuB centre, which needs to be fully 
reduced in order for molecular oxygen to bind to it. Electrons released from cytochrome c to CuA 
centre are quickly distributed to heme a and from there to the heme a3-CuB centre (Stiburek et al, 
2006). The reduced heme a3-CuB centre binds O2, which is guided to CuB by an O2 transfer pathway 
in Cox3. O2 receives one electron from Fe2+ of heme a3 and forms O2-, which stays bound to Fea32+. 
The rest of the electrons are transferred to O2- after a water molecule has been fixed to the reaction 
site in order to produce two H2O molecules out of O2 (Yoshikawa et al, 2012). 
 
Figure 2.2. COX assembly pathway. In addition to all the subunits, prosthetic groups and enzymes/proteins needed 
for their preparation are presented in the picture, in the propoced sequential order. S1, S2 and S3 denote the 
subcomplex intermediates and S4 represents the final 13-subunit enzyme complex. Picture modified from 
Fornuskova et al, 2010. 
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The side of the enzyme facing the matrix has hydrophilic pores that are thought to function in 
proton translocation. Proton translocation through the channels happens with the aid of hydrogen 
bonds that form between water molecules and hydrophilic amino acids lining the channel 
(Tsukihara et  al, 1996). Two of these cavities presumably form pathways connecting to the O2 
reduction site. These pathways are named the D- and K-pathways and they supply the protons used 
to generate water from O2 (Yoshikawa et al, 2011). The D-pathway is probably branched, because it 
can direct protons to the active site of the enzyme and to the other side of IMM (Tsukihara et  al, 
1996; Yoshikawa et  al,  2011).  There  is  also  a  third  pathway,  the  H-pathway.  However,  the  H-
pathway is thought to function only in transferring protons to the IMS (Yoshikawa et al, 2011). All 
of the pathways reside inside Cox1, which has many transmembrane helices that form hydrophilic 
pores (Tsukihara et al, 1996). 
 
2.3 Alternative respiratory enzymes 
 
2.3.1 Alternative oxidase 
 
A distinctive feature between the respiratory chains of mammals and plants is that the plant 
respiratory chain can be branched, i.e. there are more potential routes for electrons than the one 
depicted above in section 2.1.3. Branching of the respiratory chain is enabled by alternative 
respiratory enzymes, the most relevant being the cyanide-resistant alternative oxidase (AOX). AOX 
is a single subunit protein that transfers electrons from ubiquinol to molecular oxygen reducing it to 
H2O, without pumping protons from the matrix to the intermembrane space (Rustin and Jacobs, 
2009). Thus, it bypasses complexes III and IV of the respiratory chain, and the ATP production 
capacity of mitochondria is therefore lowered (McDonald et  al,  2009).  However,  AOX  has  the  
ability to keep the respiratory chain (and proton pumping through complex I) active in situations 
where the cytochrome pathway is blocked. AOX is thought to exist as a homodimer, although 
monomers are known to exist and function in physiological conditions (Siedow and Umbach, 
2000). Most structural studies performed on AOX have involved strategies utilizing mutagenesis of 
the polypeptide chain (Albury et  al, 2002), and there has been no crystal structure data of the 
enzyme until very recently (Shiba et  al, 2013). The interlocked cylindrical monomers present a 
hydrophobic face on one side and a hydrophilic face on the other. Association into the IMM most 
likely happens in an interfacial fashion via the hydrophobic surface. The active site of the enzyme is 
a non-heme di-iron centre, buried within a four-helix bundle. Four glutamate and two histidine 
residues coordinate the iron atoms (Shiba et al, 2013). AOX stays inactive in normal physiological 
conditions where cytohrome pathway is not blocked, because the high Km value of AOX for 
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reduced quinones does not allow it to compete with the cytochrome pathway (Rustin and Jacobs, 
2009). Activity of the enzyme is regulated by metabolic intermediates, particularly Į-keto acids 
(e.g. pyruvate) and succinate (Siedow and Umbach, 2000).  
 
The alternative oxidase is widely found in plants and fungi, but also in some protists and also 
recently in animals (McDonald et al, 2009). However, AOX seems to be present only in relatively 
primitive animal phyla, as it is not found in vertebrates or arthropods (Rustin and Jacobs, 2009). 
AOX is thought to provide metabolic flexibility to plants that live in variable developmental and 
environmental conditions (Berthold et  al,  2000).  AOX  expression  has  also  been  shown  to  lower  
ROS production in plants (Maxwell et al, 1999). In animals, AOX expression has been proposed to 
allow worms to inhabit environments with low pH and toxic sulphites (McDonald et al, 2009). 
AOX may also suppress ROS production by preventing over-reduction of the respiratory chain in 
situations where COX is inhibited (e.g. plant parasites that encounter cyanogenic compounds 
excreted by the host plant, that inhibits COX) (McDonald et al, 2009). 
 
It  has  been  proposed  that  AOX  could  be  used  to  alleviate  symptoms  of  mitochondrial  diseases,  
because it naturally functions in highly reducing conditions that are also observed in patients with 
mitochondrial diseases. Therefore there has been considerable effort to test whether AOX could be 
expressed beneficially in mammalian cells and in mitochondrial disease model animals, mainly in 
Drosophila melanogaster and mouse (Rustin and Jacobs, 2009). The AOX gene from the ascidian 
Ciona intestinalis has been expressed in human cells and it has been shown to confer cyanide 
resistance as well as compensate the deleterious effects of cytochrome c oxidase deficiency 
(Hakkaart et  al, 2006; Dassa et  al, 2009b). More recently, a mouse model expressing AOX was 
developed (El-Khoury et  al,  2013).  In  the  paper,  AOX  expression  was  shown  to  confer  cyanide  
resistance and decrease ROS production in mice with respiratory chain blockage. The Drosophila 
melanogaster models expressing AOX are discussed in section 2.3.3. The tests done on the human 
cell and whole animal models indicate that AOX is a useful tool for compensating symptoms 
resulting from respiratory chain deficiencies and therefore it should be considered (long-term) as a 
gene therapy tool for mitochondrial diseases in future. 
 
2.3.2 Alternative NADH dehydrogenase 
 
The mammalian complex I, which is composed of 45 different subunits (Lazarou et  al, 2009), is 
replaced in the budding yeast, Saccharomyces cerevisiae,  with a single polypeptide from the NDI 
family. Ndi1 is a single subunit rotenone-insensitive NADH-quinone oxidoreductase, which 
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associates  into  the  matrix  side  of  the  IMM.  Ndi1  does  not  couple  electron  transfer  to  proton  
pumping (Yagi et al, 2001). It is the primary entry point of electrons of the yeast respiratory chain. 
The same type of enzyme (bypassing complex I but not translocating protons) is found in plants and 
bacteria, but not in mammals (Iwata et  al, 2012). Ndi1 is also an alternative respiratory enzyme, 
because it can bypass complex I of the mammalian respiratory chain. It has been proposed that Ndi1 
could also be utilized as a therapeutic tool to compensate complex I deficiency in mitochondrial 
disease patients (Yagi et al, 2001). 
 
The yeast Ndi1 exists as a homodimer under physiological conditions, much like AOX. On one side 
of the dimer there is a hydrophobic ridge that is lined with positively charged patches. This is most 
likely the surface that anchors the enzyme into the IMM (Iwata et al, 2012). The active site of the 
enzyme features an FAD cofactor that is bound to the enzyme noncovalently. Unlike the 
mammalian complex I, Ndi1 does not have any iron-sulfur clusters (Yagi et al, 2001). The binding 
sites for NAD+ and quinone are overlapping, which suggests that the electron transfer reactions 
happen in a ping-pong mechanism (Iwata et  al,  2012).  Ndi1 seems also to operate according to a 
two-electron reaction mechanism, whereas complex I works via a one-electron mechanism (Yagi et 
al, 2001). 
 
As stated above, Ndi1 has also been studied as a potential therapeutic tool for complex I deficiency. 
In fact Ndi1 has been expressed in human cells and it has supported the growth and survival of cells 
even in conditions where complex I was inhibited (Seo et al, 2000). Ndi1 has also been introduced 
in the optic lobe of central nervous system in rats by means of gene transfer (Marella et al, 2010). In 
the experiment, vision of rats suffering from Leber’s hereditary optic neuropathy (which is due to 
mutations in genes coding for complex I subunits) was restored to normal level after introduction of 
Ndi1, even though it was severely impaired because of the disease. This experiment was a direct 
example of the possibilites of gene therapy utilizing alternative respiratory enzymes against 
respiratory chain dysfunctotion. Studies concerning fruitfly models of mitochondrial disease with 
Ndi1 expression are discussed below. 
 
2.3.3 Alternative respiratory enzymes in D. melanogaster 
 
Drosophila models expressing alternative oxidase both constitutively and inducibly has been 
generated in Howard Jacobs’ laboratory (Fernandez-Ayala et al, 2009). The enzyme was shown to 
target mitochondria but to remain enzymatically inactive under normal physiological conditions. 
AOX expression had minimal effect on the normal phenotype of flies, with only a slight weight loss 
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in  young  adults.  It  was  able  to  alleviate  the  symptoms  of  respiratory  chain  diseases,  modeled  by  
Surf1 knockdown (which results in COX deficiency) and knockdown of the Drosophila homolog of 
the Parkinson’s disease gene dj-1ȕ. A few studies have been made where AOX has been used to 
rescue OXPHOS dysfunction specifically in the nervous system of flies (Humphrey et al, 2012). 
However, in this case OXPHOS deficiency was achieved by downregulating the catalytic subunit of 
mtDNA polymerase.  
 
The yeast alternative NADH dehydrogenase Ndi1 has also been introduced into the Drosophila 
genome and the expression of the transgene was shown to be harmless for the fly (Sanz et  al, 
2010b). Ndi1 expression was also able to rescue the detrimental phenotypes resulting from complex 
I knockdown (Cho et al, 2012; Sanz et al, 2010b). Neuronal expression of Ndi1 was also reported to 
extend the lifespan of flies with no OXPHOS dysfunction (Bahadorani et al, 2010). 
 
Ndi1 expression should not have any beneficial effect on flies with COX knockdown because Ndi1 
cannot compensate for the oxygen-reducing function of COX. Therefore in this study Ndi1 was 
used, in principle, as a control for flies coexpressing AOX under conditions of COX knockdown. 
 
2.4 Mitochondrial diseases 
 
Mitochondrial diseases commonly refer to disorders of the respiratory chain, which by estimate 
have a prevalence of 1 in 5 000 people (Ylikallio and Suomalainen, 2012; DiMauro, 2004). 
Mitochondrial diseases are a diverse group of disorders with a variety of symptoms. The disorders 
can cause symptoms in any tissue at any stage, but usually they affect organs with high energy 
demand, most commonly muscle and nervous system (DiMauro and Schon, 2008; Ylikallio and 
Suomalainen, 2012). To date there is no cure for mitochondrial diseases, only supportive measures 
that alleviate symptoms are clinically in use (Schapira, 2006). 
 
2.4.1 Molecular pathology 
 
Because of the dual genetic origin of the respiratory chain complexes, mitochondrial diseases can 
arise from mutations in OXPHOS complex genes encoded in either the mitochondrial or nuclear 
genome (DiMauro, 2004). Mutations in genes that code for proteins that participate in other 
mitochondrial functions can also cause mitochondrial diseases. These functions include 
mitochondrial protein synthesis, synthesis of assembly factors for OXPHOS complexes, import of 
cytoplasmically produced proteins, intergenomic signalling, and mitochondrial dynamics, such as 
fusion, fission and distribution (DiMauro, 2004; DiMauro and Schon, 2008). The major molecular 
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event behind the symptoms of mitochondrial diseases is believed to be ATP deficiency. When one 
or many of the respiratory chain complexes have a defect, ATP production is decreased, which can 
lead to many secondary problems. Another major cause of the symptoms is lactic acidosis, which is 
due to the secondary blockage of pyruvate dehydrogenase enzyme function. If the enzyme function 
is blocked, excess pyruvate is converted to lactate and transported out of the cells. This will lead to 
drop in pH in tissues of respiratory chain deficiency and to other secondary problems (Ylikallio and 
Suomalainen, 2012). 
 
As stated above, mtDNA exist in hundreds or thousands of copies in single cells. In a homoplasmic 
state, all the mtDNA molecules are identical, but in the heteroplasmic state mutant and wild-type 
mtDNA molecules coexist (Ylikallio and Suomalainen, 2012). In order for a mitochondrial disease 
to manifest, a certain proportion of the mtDNA molecules have to be mutated (DiMauro, 2004). 
This is called the threshold effect. The threshold for different diseases and even for different tissues 
varies. This is because a mutation in one tissue can lead to manifestation of a disease whereas the 
same mutation in another tissue can be harmless (Leonard and Schapira, 2000a). In some instances, 
the level of mutated mtDNA can affect the symptoms and nature of the disease. For example, in the 
case of mutation T8893G, if the degree of heteroplasmy is moderate (about 70 %) the mutation 
inflicts a subacute or chronic disease of young adults called NARP (neurogenic weakness, ataxia, 
retinitis  pigmentosa)  but  if  the  level  of  heteroplasmy is  very  high  (around 90  %),  it  causes  Leigh  
syndrome, a rapidly progressive encephalopathy of infancy or early childhood (DiMauro, 2004). 
 
Mitochondrial diseases are often categorized according to where the mutated gene lies (i.e. either 
mitochondrial or nuclear genome) (Leonard and Schapira, 2000a, 2000b; Ylikallio and 
Suomalainen, 2012). The most common disease caused by mutation in mtDNA is Leber hereditary 
optic neuropathy (LHON) (Schapira, 2006). It is primarily a disease of young men, which is 
characterized clinically by loss of vision due to degeneration of the retinal ganglion cells and their 
axons. The mutated genes in this disease code for core subunits of complex I and they are usually 
present in homoplasmic or high mutant heteroplasmic proportions. Other common mitochondrial 
diseases caused by mutations in mtDNA are MERRF and MELAS. Both diseases are 
encephalomyopathies, diseases that affect both nerve and muscle. MELAS (mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes) is more common of these two. The 
disease is usually caused by a common mutation (A3243G) in the gene tRNALeu, although many 
other mutations can also cause the disease (DiMauro, 2004). MELAS presents usually in children 
and adolescents and the symptoms include vomiting, seizures and dementia (Leonard and Schapira, 
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2000a). MERRF stands for myoclonus epilepsy with ragged red fibers, and typically affects young 
adults. Three mutations, all in the gene tRNALys, have been associated with the disease (DiMauro, 
2004). The disease is characterized by seizures, mitochondrial myopathy, and cerebellar ataxia. 
Among the diseases that are usually due to mutations in the nuclear genome, is COX-deficient 
Leigh’s syndrome, which is due to mutations in genes coding proteins required for COX assembly 
and biogenesis (discussed in more detail below) (Ylikallio and Suomalainen, 2012). 
 
Mitochondrial dysfunction has been identified in a number of neurodegenerative diseases including 
Parkinson’s disease, Alzheimer disease and Huntington’s disease (Schapira, 2006; Federico et  al, 
2012), although the mechanism by which it contributes to pathology are under debate. The 
accumulating mutations in mtDNA of aging neurons are thought to produce the respiratory chain 
dysfunction and the sequential ROS production that leads to neuron degeneration. Several 
mitochondrially targeted proteins seem to be involved in Parkinson’s disease pathology when 
mutated, including DJ-1 and PINK1. DJ-1 potentially acts as an antioxidant. Mutations in DJ-1 
cause increase in ROS production (Federico et al, 2012). In Alzheimer disease, oxidative stress may 
activate signalling pathways that alter amyloid precursor protein processing, which ultimately leads 
to plaque formation (a characteristic symptom of Alzheimer disease) (Lin and Beal, 2006). 
 
2.4.2 Cytochrome c oxidase related mitochondrial diseases 
 
COX deficiency is the most common cause of pathological respiratory chain defects. The diseases 
most often affect infantile or young children (Robinson, 2000). Mutations of the mtDNA-encoded 
core subunits of COX are rare, but there have been reports of COX1-3 mutations causing myopathy 
and MELAS in patients (Diaz, 2010; Ylikallio and Suomalainen, 2012). So far, only one incident of 
COX dysfunction caused by a mutation in a nuclear-coded subunit has been reported (Massa et al, 
2008). In this report, two siblings were diagnosed with severe infantile encephalopathy, which was 
due to a homozygous mutation in the COX6b1 gene. However, majority of the mutations causing 
COX deficiency affect the genes coding for auxiliary proteins. For example, mutations in assembly 
factor Surf1 are associated with COX-deficient Leigh syndrome. The function of Surf1 is not fully 
known yet, but it is thought to be involved in inserting heme a into Cox1 (Ylikallio and 
Suomalainen, 2012). The pathology of Leigh syndrome includes necrotic lesions in subcortical 
areas of the brain that lead into e.g. ophthalmoparesis, nystagmus, ataxia and dystonia (Diaz, 2010). 
COX activity in the affected tissues reduces to 10-20 % of the normal level (Robinson, 2000). 
Another example of mutated auxiliary proteins leading to COX deficiency is Sco1 and Sco2 
mutations. Sco2 mutation inflicts fatal infantile COX deficiency with the major symptoms being 
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encephalopathy and hypertrophic cardiomyopathy (Stiburek et  al, 2005). On the other hand, Sco1 
mutations seem to cause lactic acidosis and hepatic failure (Diaz, 2010). Altogether, COX 
deficiencies can cause a variety of symptoms, of which Leigh syndrome or Leigh-like diseases, 
cardiomyopathy, and liver failure are most common (Ylikallio and Suomalainen, 2012). 
 
2.5 Drosophila melanogaster animal model 
 
Drosophila melanogaster has had a major influence in biological studies, most importantly in the 
fields of genetics and developmental biology (Sánchez-Martínez et al, 2006). Many features of the 
Drosophila genome and biology still make it a good model to study many human diseases including 
neurodegenerative and mitochondrial diseases (Bilen and Bonini, 2005; Jacobs et al, 2004). 
 
2.5.1 Development and genomics of D. melanogaster 
 
The common fruit fly, Drosophila melanogaster, possesses a short generation time. A new fly 
develops from egg to adult in ten days in 25°C (Klug et  al, 2009). However, development is 
accelerated at higher temperatures and slowed when growth temperature is decreased. Before 
adulthood the fly has to go through several stages of development, which are the embryonic, three 
larval stages (1st-3rd instar) and pupal stage. Each larval stage lasts for 24 hours and metamorphosis 
inside the puparium takes 4 days to complete. The adult fly is approximately 2-3 mm long, females 
are slightly larger than males (Ashburner et  al, 2005). Females and males also differ in their 
colouration: males have a dark end of the abdomen, whereas females have a striped abdomen. Male 
flies have a row of black hairs in the middle of the first legs called sex combs that are missing in 
females, and which are used during copulation to attach the female. Furthermore, males have visible 
black hairs surrounding the reproductive parts beneath the abdomen. 
 
The full 180 Mb Drosophila genome has been sequenced (Adams et  al, 2000). The genome is 
organized into three autosomes and one sex chromosome. One of the autosomes is considerably 
smaller than the other two (only 1 Mb in size). The genome codes for roughly 13 600 proteins. 
Drosophila has all the major cell and tissue-types as humans, including a central nervous system 
composed of brain and axonal nerve trunk (central nerve cord). The mitochondrial genome in flies 
codes for the same proteins and RNA molecules as it does in vertebrates (Koc et al, 2001a, 2001b). 
All of the components of the respiratory chain, both structural and auxiliary proteins, as well as the 
apparatus for mitochondrial genome replication, genome maintenance, and mitochondrial protein 
synthesis and transport are conserved from insects to humans. 
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2.5.2 D. melanogaster as a model for human diseases 
 
There are several factors that make Drosophila useful as a model to study human diseases. First of 
all it is small and large stocks and experiments are relatively easy and cheap to maintain. The whole 
genome  of  the  fly  is  known  and  today  we  possess  many  genetic  tools  and  techniques  that  allow  
specific manipulations, including gene knockdowns and knock-ins. Non-recombining balancer 
chromosomes further aid in these manipulations. Lastly, phenotypic characters can be quantified by 
carefully designed experiments (Jacobs et al, 2004; Sánchez-Martínez et al, 2006). Because of the 
long and continuous use of Drosophila, many biological pathways have been elucidated in the fly 
and it has spurred the creation of many publicly available databases (FlyBase, FlyAtlas). 
 
Drosophila has been used to study neurodegenerative diseases, cancer, cardiac pathologies and 
mitochondrial diseases (Sánchez-Martínez et al, 2006). Humans and flies share many fundamental 
biological pathways, although some are simplified in flies (Jacobs et  al, 2004). As stated above, 
both  have  similar  cell  types  that  compose  similar  organ  and  organ  systems.  Drosophila has also 
been shown to possess orthologs for ~60 % of genes that are known to cause diseases in humans 
(Rubin et al, 2000). 
 
The neurodegenerative disease models include those for Parkinson’s disease, Alzheimer disease and 
Huntington’s disease (Bilen and Bonini, 2005). Parkinson’s disease has been modelled by mutating 
parkin gene in flies, which results in dramatic degeneration of muscle cells with deformed 
mitochondria. The flies also present an abnormal wing phenotype, but no loss of dopaminergic 
neurons. Another Parkinson’s disease model was made by mutating the gene dj-1ȕ, a fly homolog 
of DJ-1, a gene that is associated with Parkinson’s disease when mutated (Fernandez-Ayala et  al, 
2009). Alzheimer disease has been modelled by expressing the mutant human amyloid precursor 
protein in flies (Bilen and Bonini, 2005). The same type of strategy was used in a study by Bodai et 
al (2012), when mutant huntingtin protein was expressed in flies. 
 
Mitochondrial diseases have been simulated extensively on Drosophila. One such model is the 
technical knockout mutant fly (tko), which has a mutation in the mitochondrial gene coding for 
mitoribosomal subunit S12 (Toivonen et  al, 2001). The mutation causes impaired mitochondrial 
protein synthesis, leading to a phenotype characterized by developmental delay, bang sensitivity 
(paralysis through mechanical stress) and deafness. Studying tko flies can produce answers as to 
what happens in mitochondria with insufficient protein synthesis (Jacobs et al, 2004). Many studies 
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have taken advantage of available methods to manipulate the Drosophila genome and produce 
mitochondria specific gene knockdowns (Zordan et al, 2006; Fernandez-Ayala et al, 2009). These 
methods inlcude post-transcriptional gene silencing via RNA interference (RNAi) and expression of 
RNAi  constructs  with  binary  GAL4 -  upstream activating  sequence  (UAS)  system.  Both  of  these  
methods were used in this study and they are further described below. 
 
2.5.2.1 Transgenic RNAi fly lines 
 
RNA interference (RNAi) is best known as a way for cells to silence unwanted gene expression via 
small complementary RNA molecules. The mechanism is also used by cells to protect against 
transposable DNA elements and also to regulate chromatin structure (Moazed, 2009). There are 
actually different types of RNAi events, depending on the RNA molecule that is used as a template 
to direct gene silencing. All of the “classic” small RNA molecules are 20-30 nucleotides long 
(Krebs et  al, 2011). They are produced from longer double-stranded precursor molecules by a 
ribonuclease called Dicer. Small RNA molecules are then loaded into the RNA-induced silencing 
complex (RISC), which is the protein responsible for target RNA molecule degradation. The RISC 
complex is built around the Argonaute core protein (Krebs et al, 2011). Argonaute binds the small 
guiding RNA and it also possesses an RNase H type nuclease domain that cuts the target molecule 
(Moazed, 2009). 
 
Vienna Drosophila RNAi  center  (VDRC)  holds  a  library  of  transgenic  RNAi  fly  lines  that  are  
publicly available. The library encompasses over 30 000 different transgenic lines that together 
cover almost 94 % of fly genes. The transgenic flies express a double-stranded hairpin RNA 
(shRNA) molecule that guides the RISC complex to a specific target RNA (Dietzl et al, 2007). The 
shRNA sequence is complementary to the gene sequence that is targeted for knockdown. The 
transgenic UAS-RNAi fly lines were first created using P-element-based method, which utilized 
random insertion of the transgene into the fly genome. The problem with this method is the high 
occurrence of false negatives due to insertion of the transgene in the middle of another vital 
housekeeping gene. To eliminate the false negative, another method based on phiC31 site-specific 
integration  was  developed  (Ni et  al, 2007). This method allows insertion of the UAS-RNAi 
transgene to specific site in the fly genome. Both P-element and phiC31 derived transgenic lines are 
represented in VDRC. In both cases, expression of the UAS-RNAi transgene needs to be induced 
by the binary GAL4-UAS system. 
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2.5.2.2 GAL4-UAS expression system 
 
The GAL4-UAS system was originally found from budding yeast Saccharomyces cerevisiae, where 
its function is to induce gene expression in situations when galactose is the only available source of 
catabolic energy (Krebs et al, 2011). GAL genes code for a group of enzymes related to galactose 
metabolism. All the GAL genes are under the control of the UAS enhancer, which itself is under the 
control of a positive regulator, GAL4. GAL4 has a DNA-binding zinc-finger domain, and binds to 
DNA  as  a  dimer.  The  GAL4-UAS  system  has  later  on  been  adapted  for  use  to  drive  the  
heterologous expression of transgenes both in flies and also in human cells (Brand and Perrimon, 
1993; Webster et  al, 1988). Both the UAS site and GAL4 have been mutagenized in order to 
establish an optimal binding site for GAL4 and also to achieve efficient transcription activation in 
flies (Brand and Perrimon, 1993). Tissue specific or constitutively expressed GAL4 and the UAS-
transgene are carried in different parental fly lines and the transgene expression is induced in the 
progeny flies after crossing (McGuire et  al, 2004). This allows the viability of parental lines 
carrying toxic products since neither expresses the transgene by itself i.e. UAS-transgene lines do 
not have the expression enhancer and the driver lines do not carry any transgene to drive (although 
they express GAL4 in specific tissues or developmental stages). Other advantages include the 
versatility of the system: any GAL4 driver line can be crossed with any UAS transgene line to 
induce expression. There are thousands of available GAL4 lines and they have been pooled in the 
Gal4 Enhancer Trap Insertion Database (GETDB) (Hayashi et al, 2002). With the enhancer trap 
system, GAL4 is inserted in the genome randomly under the influence of generic tissue specific 
enhancers (McGuire et al, 2004). The only drawback of this system is that the expression cannot be 
fully regulated. GAL4 expression is guided by the enhancer and the UAS-transgene is expressed 
whenever there is GAL4 present. 
 
In order to induce transgene expression at specific time and place, several modifications of the 
GAL4-UAS system have been developed. One of these modifications takes advantage of the natural 
repressor of GAL4, GAL80. In yeast when galactose is absent, GAL80 binds to GAL4 and prevents 
it from binding DNA (Krebs et al, 2011). When galactose is present, it releases GAL80 from GAL4 
and GAL4 is free to induce expression of GAL genes. A temperature-sensitive variant of GAL80 
(GAL80ts) has been constructed for expression under the tub-promoter in Drosophila (McGuire et 
al, 2004). In this system, GAL80ts is ubiquitously expressed and thus disables GAL4. The 
expression is induced when GAL80ts is degraded by placing flies in high temperature (approx. 
32°C). The system is named TARGET for temporal and regional gene expression targeting. 
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Another system combines GAL4 with a hormonal response. Two chimeric proteins have been 
constructed:  one  is  a  GAL4-estrogen  receptor  fusion  (GAL4-ER)  and  the  other  is  a  GAL4-
progesterone receptor fusion (GeneSwitch). In the GeneSwitch system, expression is induced by 
feeding the flies with an anti-progestin drug, RU486. The benefit of this system is that the 
expression level can be controlled by varying the concentration of RU486 that is fed to the flies. 
Other  systems  include  the  FLP  recombinase  recognition-GAL4-UAS  system,  in  which  a  
transcriptional-termination cassette is inserted between the promoter and GAL4 or between UAS 
and transgene. The cassette is removed by FLP recombinase, which is cloned downstream of a heat-
shock promoter. Thus expression can be induced by heat-shock treatment. However, this treatment 
can be done only once and the transgene expression stays active thereafter (McGuire et al, 2004). 
23 
 
3.  AIMS OF THE RESEARCH 
 
The aim of this master’s thesis is to 
1. Characterize the phenotype of nervous system specific knockdown of cytochrome c 
oxidase in Drosophila melanogaster and 
2. Test whether alternative oxidase can rescue the deleterious phenotypes. 
The hope is that the results will give more insights into the pathology of COX deficiencies and 
provide a better understanding of whether/how AOX function can alleviate the pathological 
phenotypes. With the help of this information, AOX can one day be evaluated as a potential 
therapeutic tool for OXPHOS disorders. 
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4. MATERIALS AND METHODS 
 
4.1 Fly stocks and maintenance 
 
4.1.1 Fly stocks 
 
Drosophila melanogaster driver lines are presented in Table 4.1 with full genotype and genomic 
location. Homozygous Nrv2-GAL4 and elav(3)-GAL4 stocks were crossed with  and 
 balancer stocks, respectively, in order to establish balanced driver lines. The UAS-RNAi 
lines from Vienna Drosophila RNAi center (VDRC) are shown in Table 4.2 with genomic location, 
insertion type and target gene of silencing. In addition, existing stocks of flies expressing both an 
RNAi  construct  and  a  transgene  (AOX  or  Ndi1)  were  used  as  well  as  GFP  reporter  lines.  These  
stocks are shown in Table 4.3 with their notation, genotype, phenotypic character and a reference to 
the original paper where AOX or Ndi1 transgenic lines were created. 
 
4.1.2 Fly food media 
 
Fly stocks and all the experiments were carried out in standard high sugar fly food medium, 
composed of 1.5 % (w/v) sucrose (Sigma-Aldrich), 3 % glucose (AnalaR Normapur®, VWR), 3.5 % 
active dry yeast,  1.5 % maize flour,  1 % wheat germ, 1 % soya flour,  1 % agar (Oriola) and 3 % 
treacle, to which was added 0.1 % Nipagin M (Sigma-Aldrich) and 0.5 % (v/v) propionic acid 
(Acros Organics). 
 
4.1.3 Environmental conditions 
 
During the characterization of knockdown phenotype and producing flies for imaging, flies were 
kept in incubators at 25°C with a 12 h-12 h day-night cycle. Stock bottles were kept in the fly 
laboratory at room temperature. 
 
 
Driver line  
(BL number) Genotype Genomic location Comments 
Nrv2-GAL4 (6800) w*; P{nrv2-GAL4.S}3 2 GAL4 expressed exclusively in 
the nervous system 
elav-GAL4 (8760) w*; P{GAL4-elav.L}3 3 Expresses GAL4 in the nervous 
system 
elav-GAL4 (458) P{GawB}elavC155 X 
GAL4 expressed in all tissues of 
the embryonic nervous system 
beginning at stage 12 
 
Table 4.1. Neural specific GAL4 driver lines. Line name, genotype, genomic location and comments. 
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Transformant ID Genomic location Insertion type 
Gene targeted 
for silencing 
109338 X Targeted CoIV, COX IV 
30892 3 Random CoVb, COX Vb 
 
 
Line  Genotype Genomic location Comments 
COX IV-KD;AOX 
 
2 (RNAi), 3 (AOX) Fernandez-Ayala et al, 2009 
COX IV-KD;Ndi1 
 
2 (RNAi), 3(Ndi1) Sanz et al, 2010b 
COX Vb-KD;AOX 
 
2 (AOX), 3 (RNAi) Fernandez-Ayala et al, 2009 
COX Vb-KD;Ndi1 
 
2 (Ndi1), 3 (RNAi) Sanz et al, 2010b 
stinger-GFP w1118;UAS-stinger-GFP;+ 2 Viable and fertile 
mCD8-GFP 
 
2 Viable and fertile, curly wings 
  
4.2 Determination of COX knockdown phenotype with and without AOX rescue 
 
4.2.1 Lethality assay 
 
Three replicates of each individual cross were made and 10-12 virgin females and 5-6 males were 
used in each cross. Parental flies were left to copulate for three days, after which they were 
transferred to fresh fly food vials and left to copulate for two days. Finally the parental flies were 
discarded. Vials were kept in the +25°C incubator and water was added every second day to prevent 
drying of the food. Eclosing flies were counted once a day in the afternoon for 9 days. Numbers of 
eclosing flies from the two successive vials (with same parental generation) were added together 
before analysing results. Therefore there are three data points for each individual cross in a lethality 
experiment. IBM SPSS Statistics (v.19) were used to quantify statistical differences using student’s 
t-test. Each individual experiment was repeated twice. 
 
4.2.2 Survival assay 
 
The survival experiments were essentially life span experiments (see Sanz et al, 2010a), with some 
important differences. Three parallel crosses were made and 10-12 virgin females and 5-6 males 
Table 4.2. RNAi construct lines. Transformant ID, genomic location, insertion type and gene targeted for 
silencing. 
Table 4.3. Existing transgenic D. melanogaster lines. Line name, genotype, genomic location of transgene(s) and 
phenotype 
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were used in each cross. Knockdown expressing flies were collected using CO2 at  the  day  of  
eclosion and kept in standard fly food vials, 10 flies per vial, males and females in separate vials. 30 
flies of each genotype were collected. Flies were kept in a +25°C incubator with 12 h light-dark 
cycle. Flies were tipped into fresh vials every 2-3 days and dead flies were counted. The phenotype 
and activity of flies was also observed during the experiment. The experiment lasted two weeks, 
after which all vials were discarded. The percentage of living flies was recorded and survival curves 
were drawn using Microsoft Excell (2010). Each individual experiment was repeated twice. 
 
4.3 Preparation and imaging of fly sections 
 
4.3.1 Sectioning of paraffin embedded flies 
 
Flies were fixed in 4 % formaldehyde for several hours (3-5 h). Prior to fixation the abdomen and 
wings were removed with dissection forceps (see 4.4.2). Fixed flies in cassettes were transferred to 
paraffin infiltration machine (Sakura Tissue-Tek VIP® 4). The paraffinization program used is 
illustrated in Table 4.4. 
 
 
Reagent Conc. Time (h:mm) Temp. (°C) 
Ethanol 70 % 1:00  
Ethanol 80 % 1:00  
Ethanol 90 % 1:00  
Ethanol 100 % 1:30  
Ethanol 100 % 1:30  
Xylene  1:00  
Xylene  1:00  
Xylene  1:30  
Paraffin  1:30 58 
Paraffin  1:00 58 
Paraffin  1:00 58 
Paraffin  1:00 58 
 
Paraffin infiltrated flies were embedded in paraffin blocks individually, on a Sakura Tissue-Tek 
Embedding Console System. Flies were positioned so that the plane of cutting will be from dorsal 
to ventral side. Fly blocks were stored at +4°C. 
 
Table 4.4. Paraffin infiltration program. Reagent, concentration, time of incubation and temperature. 
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4 ȝm slices were cut from fly blocks with Microm HM310 rotation microtome. Slices adhered to 
Superfrost plus microscope slides (Thermo Scientific) were left at +37°C overnight to dry 
completely  and  attach  to  the  slides.  Paraffin  was  removed  from  dry  sections  with  xylene  and  a  
descending alcohol treatment, which is illustrated in Table 4.5. 
 
 
Solution Conc. Time 
Xylene  5 
Xylene  5 
Xylene  5 
Ethanol Abs. Short 
Ethanol Abs. Short 
Ethanol 90 % Short 
Ethanol 90 % Short 
Ethanol 80 % Short 
Ethanol 80 % Short 
Ethanol 70 % Short 
Ethanol 70 % Short 
dH2O  Short 
4.3.2 Immunofluorescence staining and imaging with confocal microscope 
 
Deparaffinated slides were rinsed with TBS-Tween before Heat Induced Epitope Retrieval (HIER) -
treatment, in which samples were incubated for 30 minutes in +95°C citrate buffer. Citrate buffer 
was made dissolving 1.92 g anhydrous citric acid with 0.74 g EDTA into 1000 ml of distilled H2O. 
The pH of solution was then adjusted to 6.2 and 0.5 ml of Tween 20 was added. The HIER-treated 
slides in the buffer were then cooled to room temperature (RT) on ice and slides were rinsed with 
TBS-Tween. Tissue sections were permeabilized by incubating them in 0.3 % Triton X-100 in TBS-
Tween for 30 minutes in room temperature. Slides were washed after permeabilization with TBST 
(3 x 5 minutes). Sections were blocked with 5 % bovine serum albumin (BSA) in TBST overnight 
in +4°C. Primary antibodies were added in 5 % BSA in TBST solution and incubated for one hour 
at  RT (list  of primary and secondary antibodies in Tables 4.6 and 4.7).  Primary antibody solution 
was washed away with TBST (3 x 10 minutes) before applying the secondary antibody cocktail, 
also in 5 % BSA in TBST solution and before incubation for one hour at RT. Slides were washed 
again with TBST (3 x 10 minutes) and a cover glass was mounted with ProLong Gold with DAPI 
(Invitrogen). 
 
Table 4.5. Deparaffinization protocol. Solution, concentration and time (in minutes). 
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Antigen Antibody Manufacturer Dilution 
COX IV ab16056 Rb p Abcam 1:200 
ATP5A ab14748 Ms m Abcam 1:1000 
AOX PI047AB Rb p 21st century biochemicals 1:1000 
 
 
Antibody Manufacturer (cat #) Dilution 
Goat-anti-rabbit Alexa fluor 568 Invitrogen (A-11011) 1:1000 
Goat-anti-mouse Alexa fluor 488 Invitrogen (A-10680) 1:1000 
 
Slides were imaged using a Spinning Disc Confocal microscope (Microscope: Nikon Eclipse Ti, 
Confocal: Wallac-Perkin Elmer Ultraview, Camera: Andor EMCCD, Software: Andor iQ). Pictures 
were analysed with free software ImageJ (v. 1.45s) downloadable from the internet. 
 
4.3.3 Hematoxylin and eosin staining and imaging with light microscope 
 
Deparaffinated slides of fly tissues were stained in hematoxylin (Mayers, Merck, diluted 1:4 with 
dH2O) for 3 minutes, then washed with running tap water for 10 minutes. Washing was followed by 
staining in 0.1 % Eosin Y (Histola, glacial acetic acid added) for 40 seconds. Excess colour was 
quickly rinsed off with dH2O. Before mounting the cover slide with organic mounting medium 
(EUKITT), slides were cleared with an ascending ethanol series and xylene (same as in Table 4.5 
but in reverse order). 
 
Images of the slides were taken with an Olympus BX 51 microscope attached with an Olympus 
ColorView IIIu camera. The camera was operated via Olympus CellB software v. 2.4. Pictures were 
analysed with free software ImageJ (v. 1.45s) downloadable from the internet. Sequential pictures 
of fly brain were aligned using StackReg plugin for ImageJ. 
 
4.4 Characterization of elav-GAL4 driver expression pattern  
 
2-3 parallel crosses were made in both mating chambers and standard fly food vials. 24 or 36 
virgins and 12 or 18 males, respectively, were used for crosses in mating chambers and 12 virgins 
and 6 males were used for crosses in standard fly food vials. Flies were left to copulate in mating 
chambers for one day before starting the experiment. Microscope system used for imaging: 
Table 4.6. List of primary antibodies. Antigen, antibody, manufacturer and dilution used. 
Table 4.7. List of secondary antibodies. Antibody, manufacturer and dilution used. 
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Olympus SZX16 microscope, Olympus ColorView IIIu camera, Olympus CellB software (v. 2.4), 
Olympus U-RFL-T fluorescent lamp. 
 
4.4.1 Collection of fly embryos and first instar larvae 
 
The mating of flies was carefully timed, in order to collect embryos at a certain stage of 
development. A fresh plate (60 x 15 mm, Greiner bio-one) of fly food was added to the bottom of 
the mating chamber every two hours. Mating chambers and plates with embryos were stored at 
+25°C during the experiment. After 14-16 hours post-copulation (and assumed fertilization), 
embryos were collected from the petri dish/plate. The chorion was removed from embryos prior to 
microscopy by rolling the eggs on double sided tape. Dechorionated embryos were placed on 
standard microscope slides and a drop of 70 % glycerol was added on top of the embryos to prevent 
drying prior to microscopy. 
 
First instar larvae were collected from plates 24-36 hours post-copulation. Larvae were rinsed in 
PBS and dried on tissue. Clean larvae were placed on +4°C microscope slides (Thermo-Scientific, 
Superfrost  plus)  and  covered  with  70  %  glycerol  before  placing  a  cover  slip  carefully  on  top  of  
them. Larvae were immobilized prior to microscopy by placing them at í20°C for 10 minutes. 
 
4.4.2 Dissecting flies at various stages of development 
 
All dissections were done with Dumont #55 INOX forceps while the dissectible objects were 
submerged in PBS. 
 
4.4.2.1 Dissection of third instar larvae 
 
Third instar larvae were collected from plates 72-84 h after copulation. The posterior end of larva 
was cut away using forceps, which extrudes the internal organs of the larva. The larvae were 
grabbed by the mouth hooks and rolled inside out on top of the forceps. This way the central nerve 
cord, gut and other tissues were easily collectable. Larval muscles were pictured whilst still attached 
to cuticle. Dissected tissues were left submerged in PBS when taking pictures. 
 
4.4.2.2 Dissection of pupae 
 
Pupae were collected for dissection from vials when the eye pigmentation was visible through the 
pupal case (stages P8-P9). Pupae were attached to microscope slide with double sided tape, ventral 
side down (same way as attached to the vial).  The pupal case was opened from the anterior end 
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where the fly would eclose naturally. The puparium was then cut carefully toward the posterior end 
and loose parts of the pupal case were lifted away. After three quarters of the pupal case was 
removed, forceps were pushed under the exposed fly which then became attached to the forceps. 
The fly was then removed from the puparium. A drop of 70 % glycerol was added to prevent the fly 
from drying. An exposed fly was then pictured at this stage. 
 
The fly exposed from puparium was cut from the posterior end of the abdomen on the dorsal side. A 
small  volume of PBS was gently pipetted back and forth to remove all  loose cells from abdomen 
and thorax. The cuticle was then ripped from the posterior to the anterior end, on the dorsal side, to 
expose soft tissues for dissection. Thoracic muscles were removed at this point to expose the central 
nerve cord. The central nerve cord was lifted from the ventral side, using forceps, while it was still 
attached to the brain. After that, the brain from the head was cleaned clear of other tissues 
(especially trachea).  
 
4.4.2.3 Dissection of adult flies 
 
Flies were imaged and dissected 1 day and 5-6 days after eclosion. Adult flies were placed in an 
empty vial with a cotton swab soaked in FlyNap (Carolina Biological Supply Company). After 10-
20 min unconscious flies were collected for imaging. 
 
Dissection  of  adult  flies  started  by  removing  the  wings  and  legs,  then  the  abdomen.  Brains  were  
exposed by first removing proboscis, then cutting both compound eyes out and ripping the cuticle of 
the head to remove it, starting from the anterior. When the brain was carefully exposed, excess 
tissues attached to it were removed. Trachea was entirely removed as it interferes with fluorescent 
imaging.  The  thorax  was  cut  from  both  sides  and  then  the  dorsal  half  was  raised  to  expose  the  
central nerve cord, attached on the ventral side. Muscles were then removed from the dorsal side of 
the thorax. The central nerve cord was removed whilst still attached to the brain by carefully sliding 
forceps between the central nerve cord and the cuticle and raising the nervous tissue. Once the 
central nerve cord was loose from the ventral thoracic cuticle it was cleaned as other tissues. 
 
Internal organs are in the abdomen and those of interest were cut away by first cutting the 
abdominal cuticle from the lateral sides. Once the cuticle was removed, all organs of interest were 
easily accessible. 
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5.  RESULTS  
 
5.1 Whole organism phenotypes resulting from tissue specific knockdown of COX subunits 
 
As stated before, Kemppainen et al (unpublished) performed a preliminary experiment which 
showed that COX subunit knockdown in the Drosophila nervous system failed to produce any 
phenotype. To study the effects of nervous system -restricted COX knockdown more specifically, 
three nervous system -specific GAL4 drivers were used to drive two RNAi constructs, against COX 
IV and COX Vb subunits. The effects on the phenotype using each driver-RNAi pair were recorded 
using lethality and survival assays. AOX coexpression was then used to attempt to rescue flies with 
deleterious phenotypes. 
 
Crosses for determining the lethality of neural specific COX knockdown are presented in Appendix 
1A. Homozygous UAS-RNAi females were crossed with either heterozygous GAL4 driver males or 
hemizygous GAL4 driver males, depending on the driver. Wild-type females were crossed with 
each GAL4 driver male as a control. Crosses to determine whether AOX can rescue lethality due to 
neural specific COX knockdown are illustrated in Appendix 1B. Crosses for determining viability 
of neural specific COX knockdown are presented in Appendix 1C and the respective crosses for 
determining viability of AOX rescued neural COX knockdown flies are presented in Appendix 1D. 
 
Student’s t-test was used to evaluate statistical significance between knockdown flies and controls 
in lethality assays. However, because the number of repeats is 3 in all cases of performed lethality 
assays, reliability of the statistical tests is questionable. Although statistical significances are 
marked in the figures, they should not be considered as definitive. However, in this case the 
descriptive data on the phenotype is more important. In survival assays the statistical program 
GraphPad Prism was unable to make reliable log-rank tests on survival curves because most of the 
flies in the experiments survived the two week surveillance period (therefore they have to be 
presented as 0 in the data which means that they are censored from the original input data). 
Descriptive data collected during the survival assay is therefore very important. 
 
5.1.1 Neural specific knockdown using Nrv2-GAL4 driver has no effect on phenotype 
 
Neuronal knockdown of COX subunits was tested with an Nrv2-GAL4 driver that was previously 
tested by Kemppainen et al (unpublished). In that experiment, knockdown of COX Vb and COX 
VIb  did  not  affect  the  viability  of  flies.  I  repeated  this  experiment,  this  time  with  RNAi  against  
COX IV and COX Vb. The Nrv2-GAL4 driver was balanced over CyO balancer chromosome (see 
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materials and methods 4.1.1). Once again, Nrv2-GAL4 driven COX knockdown did not affect the 
viability of flies (Figure 5.1). There was a slight difference between the numbers of eclosing COX 
IV knockdown flies and wild-type flies, in both sexes, but it was within standard deviation. There 
was no statistical difference between knockdown flies and wild-type flies, in either sex, or when 
compared to internal controls (flies with balancer chromosome). The phenotype of the knockdown 
expressing flies was identical to wild-type at the day of eclosion, meaning that flies were flying and 
jumping actively around the vial. 
 
 
 
 
The effect of Nrv2-GAL4 driven COX subunit knockdown on degeneration of flies was tested with 
a survival assay. The experimental set-up differed from the lethality assay, so that all progeny flies 
were expressing the RNAi constructs (see crosses in Appendix 1). During the two-week 
surveillance  period,  the  phenotype  of  knockdown  flies  was  the  same  as  that  of  wild-type  flies.  
Knocking down either COX subunit  did not seem to have any degenerative effect  (Figure 5.2).  A 
few COX Vb knockdown male flies died during the experiment but 90 % stayed alive. A few deaths 
also occurred of wild-type female and male flies, so the observed attrition might be considered 
natural variation. 
 
Since Nrv2-GAL4 driven knockdown was not able to produce any kind of phenotype, the driver 
was discarded from further experiments.  
Figure 5.1. Mean number of eclosed flies after Nrv2-GAL4 driven COX subunit knockdowns. Plus sign in the 
legend denotes flies with Nrv2-GAL4 driver and a minus sign denotes flies without the driver (flies with balancer). 
Means are presented ± SD. No statistical differences were observed. See Appendix 1 for further details of crossing 
scheme. 
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5.1.2 Neuronal knockdown using 3rd chromosomal elav-GAL4 driver 
 
5.1.2.1 Knocking down COX IV subunit using elav(3)-GAL4 produces a partially lethal 
phenotype 
 
Elav(3)-GAL4 driver (Bloomington stock centre number 8760) was also tested in the preliminary 
experiment of Kemppainen et al (unpublished). At the time, it did not produce a phenotype when it 
was driving knockdown of COX subunits Vb and VIb. The test was repeated, and for this elav(3)-
GAL4 driver was balanced over Sb balancer chromosome (see materials and methods 4.1.1). A 
lethality  assay  was  performed,  which  verified  that  elav(3)-GAL4  driven  knockdown  of  COX  
subunit Vb did not produce a lethal phenotype in flies (Figure 5.3). Knockdown flies had the same 
phenotype as wild-type flies at the day of eclosion: they were active, flying and jumping around the 
vial. However, when the elav(3)-GAL4 driver was used to drive knockdown of COX IV, a partially 
lethal phenotype was produced. Most of the eclosing flies dropped from the pupa to the bottom of 
the vial and got stuck on the fly food. They were not able to move or get out from the food so most 
of them died in first few hours after eclosion. In addition to the flies with “weak” phenotype, there 
were a few flies eclosing that had a wild-type locomotor phenotype, but they were the minority.  
 
Figure 5.2. Survival of flies when COX subunits were knocked down using Nrv2-GAL4 driver. More than 90 
% of flies from all genotypes survive the experiment period. The number of flies in the experiment was 30 for COX 
IV-KD males, COX IV-KD females and wild-type male flies, 29 for COX Vb-KD females and COX Vb-KD males 
and 23 for wild-type females. 
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5.1.2.2 Knocking down COX IV subunit using elav(3)-GAL4 degenerates flies 
 
Because COX subunit Vb knockdown did not produce any phenotype, only COX IV knockdown 
flies were collected for the survival assay. Flies were collected from a cross between homozygous 
UAS-RNAi females and homozygous elav(3)-GAL4 –males (see Appendix 1 for crossing scheme). 
As  a  control,  wild-type  females  were  crossed  with  homozygous  elav(3)-GAL4 –males. Some 
eclosing COX IV knockdown flies got stuck in the food, as in the lethality assay, but these were not 
collected for the survival experiment. Both male and female flies collected for the experiment were 
weak compared to wild-type flies at the day of eclosion. Half of the knockdown males died one day 
into  the  experiment,  as  can  be  seen  from  Figure  5.4.  After  two  weeks  only  21  %  of  male  
knockdown flies were alive. Knockdown female flies did not die as frequently as male knockdown 
flies, 88 % were still alive after two weeks. Both female and male knockdown flies were immobile 
for  the  two weeks.  They  did  not  fly  or  move  even  when the  vial  was  picked  up.  Both  males  and  
females preferred lying still on the wall of the vial. However, if they dropped to the bottom of the 
vial, they were able to climb back up to the wall. All wild-type females and males survived the two 
week period. 
 
Figure 5.3. Mean number of eclosed flies when COX subunit knockdown is driven with elav(3)-GAL4 driver. 
Number of individual repeats for each genotype is 3 (as it was with Nrv2-GAL4 driven lethality assay). Mean 
numbers are presented ± SD. Plus sign in the legend denotes flies with elav(3)-GAL4 driver and a minus sign 
denotes flies without the driver. An asterisk represents statistically significant difference when the mean values are 
compared to those of wild-type flies (p<0.05, Student’s t-test). No statistically significant difference was observed if 
number of eclosed knockdown flies was compared to number of internal control flies. 
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5.1.3 Neuronal knockdown using X-chromosomal elav-GAL4 driver 
 
5.1.3.1 Knocking down COX subunits by elav(X)-GAL4 produces lethal phenotypes 
 
A third neuron-specific driver, X-chromosomal elav-GAL4, was chosen to drive the expression of 
transgenes because it was postulated to be more efficient than the third chromosomal driver. 
Because Drosophila males carry only one X-chromosome, the experimental crosses were performed 
so that only female offspring express the knockdown and male offspring act as a control group for 
the females (see crosses in  Appendix 1). 
 
Only a few COX IV knockdown females were able to eclose in the experiment (Figure 5.5). The 
eclosing females were extremely weak: they fell to the bottom of the vial and were unable to move. 
They were unable to inflate their wings. All these females died soon after eclosion. The respective 
control males had the same phenotype as wild-type controls, they were flying and jumping around 
the vial actively. The phenotype of elav(X)-GAL4 driven COX IV knockdown females resembled 
the phenotype of elav(3)-GAL4 driven COX IV knockdown flies. Knocking down COX Vb using 
elav(X)-GAL4 also produced a semilethal phenotype. There were significantly less females 
eclosing than males.  However,  knocking down COX subunit  Vb did not change the phenotype of 
the flies that reached eclosion: knockdown females were active and flying around the vial just as 
much as wild-type flies. 
Figure 5.4. Survival of flies when COX subunit IV was knocked down using elav(3)-GAL4 driver. All wild-
type flies, both male and female, survived through the two week experiment. The number of flies in each group was 
29, 19, 30 and 30 for COX IV-KD female, COX IV-KD male, wild-type female and wild-type male, respectively.  
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5.1.3.2 Knocking down COX subunit Vb by elav(X)-GAL4 produces a degenerative 
phenotype 
 
The survival assay for flies knocked down for COX IV or COX Vb using the elav(X)-GAL4 driver 
was again set up in such a way that all the offspring were expressing the RNAi construct (see 
Appendix 1). No viable COX IV knockdown flies (of either sex) eclosed, so the measurement could 
not be performed on these flies. COX Vb knockdown produced a strong phenotype in males, but 
less  strong  in  females,  which  manifested  the  same  phenotype  as  wild-type  flies  at  the  day  of  
eclosion. Eclosing knockdown males were very weak. Most dropped to the bottom of the vial and 
got stuck in the food. They had essentially the same phenotype as COX IV-KD females. Some male 
flies were less severely affected and were transferred to new vials with fresh fly food for the 
survival experiment. These males were still very weak and preferred lying still on the wall of the 
vial. One week into the experiment, the male flies started to die off and after two weeks only 10 % 
were  alive  (Figure  5.6).  COX  Vb-KD  females  appeared  normal  on  the  day  of  eclosion  but  they  
quickly turned immobile and remained still on the wall of the vial. They were slow in getting back 
up if they dropped to the bottom of the vial. However, more than 90 % of the females survived the 
two week period, even though their phenotype was severely affected due to the knockdown. 
 
 
Figure 5.5. Mean number of eclosed flies when COX subunit knockdown was driven using elav(X)-GAL4 
driver. In this experiment female flies are expressing the knockdown and males are an internal control. Mean 
numbers are presented ± SD. An asterisk represents statistically significant difference when knockdown females are 
compared to both wild-type females and respective control males (p<0.05, Student’s t-test). 
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If the phenotype of the flies is severely affected by COX knockdowns, is the overall morphology of 
brain also affected due to the neural specific COX subunit knockdown? To answer this question 
knockdown expressing females were collected from lethality experiment and casted into paraffin 
blocks (see materials and methods section 4.3.1). Fly brains were sequentially sliced and then 
stained with hematoxylin and eosin for better view of tissue structures. In Figure A2.1 (Appendix 2) 
is a representative slice from both knockdown expressing brain and wild-type control brain. No 
apparent change in the overall morphology of the brain could be distinguished. It seems reasonable 
that flies that make it through the metamorphosis and out of the pupae have normally developed 
brain, even if they are expressing COX knockdown. If the knockdown would somehow disturb the 
formation and maturation of central nervous system, it would probably lead to death at earlier stages 
of development. 
 
 
 
 
 
 
 
Figure 5.6.  Survival  of  flies  when COX subunit  Vb is  knocked down with elav(X)-GAL4 driver. Number of 
flies in each group were 30, 21, 30 and 30 for COX Vb-KD females, COX Vb-KD males, wild-type females and 
wild-type males, respectively. 
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5.2 AOX rescue of whole-organism phenotypes resulting from neuronal specific COX 
knockdown 
 
5.2.1 AOX rescue of flies knocked down for COX IV using elav(3)-GAL4 
 
5.2.1.1 AOX rescues lethality of COX IV knockdown driven by elav(3)-GAL4 
 
Knocking down COX subunit Vb with elav(3)-GAL4 failed to produce any phenotype so AOX 
rescue experiments were not performed for these flies. Flies for the COX IV knockdown lethality 
experiment  were  collected  from  a  cross  between  homozygous  RNAi  females  with  or  without  a  
homozygous AOX transgene and homozygous elav(3)-GAL4 males. A more detailed crossing 
scheme is presented in Appendix 1. 
 
AOX coexpression made no difference to lethality (Figure 5.7). In each group more male flies 
eclosed than females. However the numbers do not provide the whole picture. COX IV knockdown 
flies were weak as in the preceding elav(3)-GAL4 driven lethality assay. Most of them got stuck in 
the fly food at the bottom of the vial and died. The ones that avoided getting stuck on the fly food 
lay still on the wall of the vial. AOX coexpressing flies on the other hand were active and were able 
to fly and jump around the vial on the day of eclosion. There were still some flies that got stuck in 
the food and died, but considerably less than in vials with flies expressing only COX IV-KD.  
 
To confirm that the possible rescue of lethal phenotype results from AOX coexpression, alternative 
NADH dehydrogenase (Ndi1) was also expressed in flies with RNAi constructs. Ndi1 is a bypass 
enzyme of complex I, therefore it should not have effect on COX knockdown (Sanz et al, 2010b). 
Ndi1 coexpressing flies were even more affected than flies with COX IV knockdown alone. All of 
the eclosing COX IV-KD;Ndi1 flies fell to the bottom of the vial and died. 
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5.2.1.2 AOX partially rescues decreased viability in flies with COX IV knockdown driven by 
elav(3)-GAL4 
 
Survival of neural specific COX IV knockdown flies rescued with AOX is presented in Figure 5.8. 
Flies coexpressing AOX survived longer than flies expressing just the knockdown. Survival 
percentages after 14 days were 100 % and 88 % for female COX IV-KD;AOX and COX IV-KD 
flies, respectively, and for males 81 % and 21 %, respectively. Flies expressing only the knockdown 
(both males and females) were weak in phenotype: they were standing still on the wall of the vial 
and did not fly or run around. They could climb back up the wall if they dropped to bottom of the 
vial. However, their movement was slow and they seemed to prefer lying still. This phenotype 
remained the same during the two week experiment. AOX coexpressing flies not only survived 
longer but there was a major difference in their phenotype compared to flies knocked down for 
COX IV. AOX coexpressing flies (of either sex) were actively flying and jumping around the vial. 
They behaved essentially as wild-type flies. Only a few deaths occurred among the COX IV-
KD;AOX  males,  but  the  remaining  stayed  active  throughout  the  two  weeks.  There  was  also  no  
change in the phenotype apart from the deaths. 
 
In the lethality experiment (see results 5.2.1.1) Ndi1 coexpression appeared to make flies even 
weaker than when they were knocked down for COX IV. COX IV-KD;Ndi1 flies also appeared 
weaker in the survival assay and died faster than flies knocked down for COX IV only (Figure 5.8). 
Figure 5.7. Mean number of eclosed flies with COX subunit IV knockdown coexpressing AOX or Ndi1 when 
expression is driven with elav(3)-GAL4. Flies express both knockdown of COX IV and a transgene illustrated in 
the X-axis. All eclosing flies are expressing knockdown and transgene if present. Statistically significant differences 
were not observed. 
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73 % and 6 % of the COX IV-KD;Ndi1 female and male flies survived the two week experiment, 
respectively. The general phenotype of the flies was the same as flies expressing knockdown only. 
They were not flying or moving but remained still on the wall of the vial. They could, however, also 
climb the wall of the vial if they dropped to the bottom.  
 
 
 
 
5.2.2 AOX rescue of flies with COX knockdown driven by elav(X)-GAL4 
 
5.2.2.1 AOX rescues lethality of flies with COX knockdown driven by elav(X)-GAL4 
 
In the X-chromosomal elav-GAL4 driven lethality assay, female progeny were expressing 
transgenes, whereas male flies act as an internal control (see crossing scheme in Appendix 1). As an 
additional control, lethality assay was performed on flies expressing both RNAi construct against 
COX Vb and GFP. The results are presented in Appendix 3. 
 
As in the previous elav(X)-GAL4 driven lethality assay (results section 5.1.3.1), COX I-KD female 
flies  were  extremely  weak  and  most  died  immediately  after  eclosion  on  the  bottom  of  the  vial.  
Some flies were unable to eclose from the pupae. Also there were fewer male flies eclosing than in 
other genotypes as was the case in the previous assay. This might be due to the fact that COX IV-
RNAi homozygous females are poor at laying eggs. Although AOX coexpression seemed to 
Figure 5.8. Survival of flies when elav(3)-GAL4 driven COX IV knockdown was rescued with AOX. Flies 
coexpressing AOX survived longer than flies with knockdown only. Flies coexpressing Ndi1 died faster than flies 
with knockdown only. This was the case for both sexes. The number of flies in the experiment in each group was 8, 
21, 22, 18, 25 and 19 for COX IV-KD;AOX female, COX IV-KD;AOX male, COX IV-KD;Ndi1 female, COX IV-
KD;Ndi1 male, COX IV-KD female and COX IV-KD male, respectively. 
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partially rescue the lethal phenotype (Figure 5.9), the eclosing females were still extremely weak 
and died immediately after eclosion. The difference in lethality is caused by the fact that there were 
more female flies surviving through pupal stage to eclosion. Some of the AOX-rescued females 
were also able to inflate their wings, something that no COX IV knockdown females could do. Ndi1 
coexpressing females were equally weak as female flies expressing only COX IV knockdown. 
 
Approximately half of the eclosing COX Vb-KD females looked normal at the day of eclosion, i.e. 
they had a wild-type phenotype. However, the other half of eclosing female flies became stuck in 
the food at the bottom of the vial and died. COX Vb knockdown produced a semi lethal phenotype 
as in the previous experiment (Results 5.1.3.1).  AOX coexpression rescues this semi lethal 
phenotype. Most of the eclosing females had a wild-type phenotype on the day of eclosion but there 
were still a few flies that got trapped in the food and died. On the other hand, Ndi1 coexpression 
seemed to make knockdown flies even weaker. There was roughly the same number of female flies 
eclosing from COX Vb-KD and COX Vb-KD;Ndi1 vials, but the majority of females coexpressing 
Ndi1 became stuck in the food after eclosion and died soon thereafter. 
 
 
 
 
 
 
 
Figure 5.9. Mean number of flies eclosed when elav(X)-GAL4 driven COX knockdown was rescued with 
AOX. Female flies are expressing the knockdown and males are internal controls. Mean numbers are presented ± 
SD. In statistical analysis both COX subunit knockdown females were compared to respective males and wild-type 
females as well as AOX females with same COX subunit knockdown. *=p<0.05, Student’s t-test.  
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5.2.2.2 AOX prevents degeneration of flies knocked down for COX by elav(X)-GAL4 
 
In the survival experiment all of the offspring were expressing both knockdown and transgenes (see 
crosses in Appendix 1). COX IV knockdown was lethal even with AOX coexpression. All of the 
flies got stuck on the food and died. Many COX IV-KD flies got stuck in the pupal case and could 
not eclose. A representative picture of flies stuck in the fly food and flies unable to eclose is 
presented in Appendix 2 (Figure A2.2). This resembles a phenotype derived from muscle specific 
knockdown of COX (Kemppainen et al,  unpublished).  There were no males eclosing in COX IV-
KD vials or COX IV-KD;Ndi1 vials. However males did eclose in COX IV-KD;AOX vials but they 
are extremely weak and died soon. Thus flies with COX IV knockdown could not be collected for a 
survival experiment. The experiment was therefore performed only on flies knocked down for COX 
Vb (and/or expressing other transgenes). 
 
The same pattern of survival was seen as in the survival experiment with elav(3)-GAL4 driven 
COX IV knockdown in section 5.2.1.2. Female flies survived longer than the corresponding males. 
AOX coexpression rescued the decreased survival caused by COX Vb knockdown. Ndi1 
coexpression with COX Vb-KD causes flies to die faster (Figure 5.10). Males expressing COX Vb 
knockdown started to die seven days into the experiment and only 10 % survived the whole two 
weeks. Males coexpressing Ndi1 with COX Vb knockdown all died within a week. Both COX Vb-
KD and COX Vb-KD;Ndi1 males remained still on the wall of the vial, although they were still able 
to fly and jump. Their movement appeared “shaky” compared to wild-type flies or those 
coexpressing AOX. This “shaky” movement was recorded in a video. Males coexpressing AOX had 
a wild-type phenotype i.e. they jumped and flew as much as wild-type flies. 93 % of these flies 
survived the two-week period. 
 
COX Vb-KD and COX Vb-KD;Ndi1 females had essentially the same phenotype as their male 
counterparts described above. 93 % and 50 % of these flies survived the two-week experiment, 
respectively. COX Vb-KD;AOX females were very active. There was no difference when they were 
compared to wild-type flies. All COX Vb-KD;AOX females survived the experiment. 
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5.3 Tissue specific UAS-AOX expression and knockdown of COX using the X-chromosomal 
elav-GAL4 driver 
 
In order to verify the functionality of the knockdown, the presence of COX subunits was detected 
from fly brain and muscle sections by staining with antibodies. Only the X-chromosomal elav-
GAL4 driven transgene expression was checked, as it produced the strongest phenotype. AOX 
expression in fly brain and muscle are presented in Figures 5.11 and 5.12. AOX  was present in the 
brain when it was coexpressed under conditions of COX subunit knockdowns. Staining of muscle 
for AOX was not expected to give any signal because the driver used was supposedly neuron-
specific. However, AOX staining is clearly visible in Figure 5.12, showing that thoracic muscles of 
the fly were coexpressing AOX upon COX subunit knockdown. Elav(X)-GAL4 driver therefore 
seems to have some activity in thoracic muscle of the adult fly. 
 
Representative immunocytochemistry images showing COX knockdown efficiency are presented in 
Appendix 4 (Figures A4.1 and A4.2). 
 
 
Figure 5.10. Survival of flies when elav(X)-GAL4 driven COX Vb knockdown is rescued with AOX. The 
number of flies in each group was 30, 30, 30, 12, 30 and 21 for COX Vb-KD;AOX females, COX Vb-KD;AOX 
males, COX Vb-KD;Ndi1 females, COX Vb-KD;Ndi1 males, COX Vb-KD females and COX Vb-KD males, 
respectively. 
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5.4 Characterization of neural GAL4 drivers by UAS-GFP expression pattern -assay 
 
The phenotype of flies with COX IV or COX Vb knockdown, driven with either elav(3)-GAL4 or 
elav(X)-GAL4,  resembled  to  some  extent  that  of  flies  with  a  muscle-specific  COX  knockdown.  
Flies became sessile progressively and were barely able to climb back up the wall of the vial if they 
Figure 5.12. Expression of AOX in fly muscle when driven by X-chromosomal elav-GAL4 driver. Scale bar 20 
µm. 
Figure 5.11. Expression  of  AOX  in  fly  brain  when  driven  by  X-chromosomal elav-GAL4 driver. AOX is 
expressed in flies knocked down for COX IV or COX Vb. Scale bar  20 µm. 
45 
 
dropped to the bottom. Also, their movement was slow and appeared shaky. Together with the 
findings from AOX immunocytochemistry (section 5.3) this suggests that the phenotypes may be 
due partly (or wholly) to COX knockdown in muscle). In order to find out the extent of driver 
“leakiness”, homozygous elav-GAL4 -driver females were crossed with homozygous UAS-GFP 
males (see crosses Appendix 1E). The mating chambers used in the crosses were covered because 
darkened surroundings encourage females to lay more eggs. The GFP expression pattern was 
recorded microscopically at all stages of development and the non-translucent stages were further 
dissected to test for GFP expression in different tissues.  
 
The results of GFP expression pattern analysis are presented in figures 5.13-5.18 for both elav-
GAL4 drivers. GFP was expressed in equal amounts using either driver and in the same tissues and 
corresponding developmental stages. In late stage embryo and in L1 larvae, GFP was expressed 
only in the central nervous system and the peripheral nerve bundles (Figure 5.13). Expression of 
GFP in third instar larvae is presented in figures 5.14 and 5.15 for elav(X)-GAL4 and elav(3)-
GAL4, respectively. At this stage, the central nervous system showed high expression of GFP but 
both drivers seem to support GFP expression also in the salivary glands. However, there is no GFP 
expression in the muscle of the larvae. Expression in pupal stage differed slightly between the two 
drivers (Figure 5.16). CNS showed high expression of GFP when driven by both elav-GAL4 drivers 
but muscle seemed to express GFP only when driven with elav(X)-GAL4. No GFP expression in 
muscle could be detected in pupae when expression was driven with elav(3)-GAL4. In adult flies 
the GFP expression pattern was similar between the two drivers (Figures 5.17 and 5.18). There was 
high expression of GFP in the central nervous system and also low expression in muscle. GFP was 
also expressed in other tissues, for example in the testis of male flies and in some parts of the 
digestive system. GFP expression pattern of muscle specific driver G14-GAL4 are presented for 
comparison in figure 5.19. The flies shown in the various images were all expressing nuclear 
targeted GFP (“stinger”: Barolo et al, 2000) unless otherwise stated. 
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Figure 5.14. GFP expression in third instar larval tissues driven by elav(X)-GAL4. A) Brain and ventral nerve 
cord, dorsal view. Salivary glands are pictured under B) visible light and C) fluorescence illumination. Muscles of 
the larva, still attached to the cuticle, are pictured under D) visible light and E) fluorescence illumination. 
Figure 5.13. GFP expression in embryo and L1 larvae driven by elav-GAL4 drivers. Embryos pictured here are 
at stage 16 (14-16 h after fertilization). GFP expression driven with elav(X)-GAL4 is presented in A) in which the 
embryo is positioned anterior down (ventrolateral view) and in B) in which the first instar larva is positioned 
anterior up (dorsolateral view). GFP expression driven with elav(3)-GAL4 is presented in C) in which the two 
embryos are both positioned anterior down. View in the left embryo is lateral, in the right embryo it is ventral. In D) 
the first instar larva is positioned anterior up (lateral view). Fly food in the gut of larvae is autofluorescent. 
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Figure 5.16. GFP expression in pupae and dissected pupal tissues driven by elav-GAL4 drivers. A) Pupa 
positioned anterior up (dorsal view). B) Pupae positioned anterior up, ventral and dorsal view. C) and D) Brain and 
ventral nerve cord. E) Dissected thoracic muscle. Dissected thoracic muscle is pictured under F) visible light and G) 
fluorescence illumination. 
Figure 5.15. GFP expression in third instar larval tissues driven by elav(3)-GAL4. A) Brain and ventral nerve 
cord, ventral view. Salivary glands are pictured under B) visible light and C) fluorescence illumination. Muscles of 
the larva, still attached to the cuticle, are pictured under D) visible light and E) fluorescence illumination. 
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Figure 5.18. GFP expression in adult fly and dissected tissues driven by 
elav(3)-GAL4. A) 1 day old adult male fly expressing UAS-mCD8-GFP 
positioned  anterior  up,  ventral  view.  B)  Testis  and  gut.  C)  Brain  and  ventral  
nerve cord. D) Thoracic muscle fibers. 
Figure 5.17. GFP expression in adult fly and dissected tissues driven by 
elav(X)-GAL4. A) 1 day old adult male fly positioned anterior up, ventral view. 
B) Rectum with GFP expression in rectal papilla cells. C) Brain and ventral 
nerve cord. D) Thoracic muscles attached to cuticle. E) Testis and gut. 
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Figure 5.19. G14-GAL4 driven muscle specific expression of GFP in different stages of fly development. A) 
First instar larva positioned anterior up. Fly food in the gut is autofluorescent. B) Early and late stage pupae 
positioned anterior up, dorsal view. C) Adult fly positioned anterior up, lateral view. D) Adult fly expressing UAS-
mCD8-GFP positioned anterior up, dorsal view. Pictures courtesy of Tea Tuomela. 
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6. DISCUSSION 
 
6.1 Knocking down COX subunits with neural specific elav-GAL4 drivers produces variable 
phenotypes 
 
Three nervous-system specific GAL4 drivers were here used to drive RNAi against two COX 
subunits (IV and Vb) in the fruit fly Drosophila melanogaster.  The  aim  was  to  see  if  any  
phenotypes would emerge due to the knockdown and whether these phenotypes could be rescued 
with AOX coexpression. 
 
The results showed that knocking down COX subunits with neural specific drivers can produce 
variable phenotypes, including full and partial lethality, locomotor disabilities and decrease in 
viability. The phenotypes produced due to knocking down COX IV were stronger than knocking 
down COX Vb, and the phenotypes were also stronger in males than in females. AOX coexpression 
was able partially to rescue the deleterious phenotypes, whereas Ndi1 coexpression made them 
worse. Two of the nervous-system specific drivers were shown to give substantial expression in the 
muscle, which is of great importance considering the aim and purpose of this research. 
 
6.1.1 Neuronal COX knockdown phenotype resembles muscle-specific COX knockdown 
phenotype 
 
Immobility and poor motor functions were found in flies with COX IV knockdown driven with 
elav(3)-GAL4 and flies with COX Vb knockdown driven with elav(X)-GAL4. Although these 
phenotypic characteristics were not quantitated, they were clearly identified in the survival 
experiment. In order to quantify the disability of locomotor action, a set of climbing tests (described 
in Fernandez-Ayala et al, 2009) should be performed on knockdown flies. Additionally, bang-
sensitivity tests (described in Toivonen et al, 2001) could be done to verify the damage caused by 
the neuronal specific knockdown. 
 
A similar type of movement dysfunction was found in flies with muscle-specific COX knockdown 
(Kemppainen et al, unpublished). In the latter experiment, COX knockdown was driven with the 
muscle-specific G14-GAL4 driver, which resulted in a phenotype of lethality at eclosion and 
locomotor dysfunction (observed as a decreased ability of the flies to climb the wall of the vial). In 
this study, the neuronal GAL4 drivers were found to cause leaky expression in the thoracic muscles 
of the flies in pupal and adult stage (discussed in section 6.1.2). Therefore it cannot be concluded 
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that the phenotype observed in flies with neuronal-specific COX knockdown, was due to effects 
solely in the neurons. The experiments carried out do not show if the phenotype resembling that 
caused by muscle-specific COX knockdown was due to inactivation or death of motor neurons or 
due to direct dysfunction of the muscle. Shaking and motor dysfunction are symptoms of many 
common neuronal diseases in humans, for example Parkinson’s disease (Dauer and Przedborski, 
2003) and multiple sclerosis (MS) (Compston and Coles, 2002), whose pathology is believed to be 
related to mitochondrial function (Winklhofer and Haass, 2010; Campbell et al, 2011). In order to 
visualize the state of neuromuscular junctions in COX knockdown flies an experiment where 
membrane-targeted UAS-GFP (“mCD8”, Lee and Luo, 1999) expression, driven by the elav-GAL4 
drivers, could be imaged. Thus it could prove if the neurons are really damaged. 
 
6.1.2 elav-GAL4 driver leakage complicates interpretation of the results 
 
The  distribution  of  the  elav  protein  (embryonic lethal abnormal visual system) was first 
characterized in a study by Robinow and White (1991), in which they saw elav to be produced only 
in post-mitotic neurons. Since then it has been widely used as a neuronal marker (Yao and White, 
1994). The elav gene promoter has also been used to construct many Drosophila lines expressing 
GAL4 specifically in neurons. The elav gene was later shown to be expressed also in glial cells of 
Drosophila nervous tissue, at least in the embryonic stage (Berger et al, 2007). 
 
In this study, elav-GAL4 drivers were shown to be giving expression in muscle, which has not been 
previously reported. The signal produced by elav-driven expression of GFP varied within the 
muscles, which could be caused by differential proteolysis of GFP in the dissected tissues. It is also 
possible that elav-GAL4 drives the expression of transgenes at a lower level in later stages of fly 
development. The GFP detected in muscle might originate from axons connecting into the muscle 
fibers of the fly. However, as was previously stated, the UAS-GFP construct used was nuclear-
targeted,  so  the  axons  should  not  harbour  any  GFP.  There  was  also  a  high  expression  of  GFP in  
salivary glands of larvae and adult Drosophila, which is possibly due to a salivary gland specific 
enhancer element in the pGawB construct (Gerlitz et  al,  2002)  that  was  used  to  make  the  elav-
GAL4 driver line. 
 
Elav-GAL4 drivers have been used by researchers to study and create different disease models in 
Drosophila, for example a model of restless legs syndrome (Freeman et al, 2012) and Huntington’s 
disease (Bodai et al, 2012). Many of the models are for neurological diseases that include 
locomotor dysfunction as symptoms. When such models are created using elav-GAL4 drivers, it is 
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possible that some phenotypic characteristics are due to expression of a target UAS-transgene in 
muscle. For example, in another study of Huntington’s disease (Agrawal et  al, 2005), the X-
chromosomal elav-GAL4 driver was used to drive the expression of mutant human huntingtin. The 
expression of this protein leads to developmental lethality. The data in the study does not show to 
which stage the flies developed before death, i.e. it does not show if the flies were dying as larvae or 
as pupae. If many flies were dying at eclosion, unable to emerge from the puparium, it is possible 
that the aggregation of mutant huntingtin was also affecting the muscle tissue. Therefore, it must be 
noted, from this point on, that knockdown using elav-GAL4 drivers must be considered as 
potentially effective in both nervous and muscle tissue. Previous experiments using elav-GAL4 
drivers should be interpreted with care, bearing in mind that the drivers are not exclusively 
neuronal. 
 
6.1.3 Phenotypes were not detected in Nrv2-GAL4 driven COX knockdown flies: probable 
late-onset effects 
 
The third neuronal driver used in this study (Nrv2-GAL4) did not produce any COX knockdown 
phenotypes in Drosophila melanogaster. The Nrv2-GAL4 driver has been shown to efficiently 
drive the expression of UAS-transgenes specifically in the nervous system (Sun et al, 1999) and it 
has also been used successfully to drive AOX expression in a Drosophila model for Parkinson’s 
disease (Fernandez-Ayala et al, 2009). Thus it seems peculiar why COX knockdown using the same 
driver, would fail to generate any phenotype. It is possible that non-intentional selection of weak 
flies, during the upkeep of the stock used in this study, has led to weaker GAL4 expression. 
 
Nrv2-GAL4 might be the only truly nervous specific driver used in this study, as it was shown that 
the other two neural specific drivers turned out to be leaking expression in the muscle. In a recent 
study mitochondrial polymerase Ȗ was knocked down in specific neuronal subpopulations using 
specific GAL4 drivers (Humphrey et al, 2012). Knocking down polymerase Ȗ lead to a loss of many 
core subunits of respiratory chain complexes that are encoded in the mitochondrial DNA, including 
COX I, II and III. The same paper also showed that neuronal respiratory chain deficiencies caused 
locomotor defects and neurodegeneration but only in aged flies. Neurodegenerative disorders in 
humans also show late-onset (Lin and Beal, 2006). Therefore, the knockdown flies studied in our 
experiments might have been too young to present any phenotype resulting from the truly neuronal-
restricted COX knockdown. 
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6.2 COX knockdown phenotype is influenced by many variables 
 
6.2.1 Influence of COX subunit knockdown on phenotype reflects its function in COX 
biogenesis 
 
As stated above, COX IV knockdown yields a stronger phenotype than COX Vb knockdown, 
regardless  of  the  sex  of  the  flies.  According  to  present  knowledge  of  COX  biogenesis,  COX  IV  
joins the multisubunit protein complex early on whilst attached to COX Va (Stiburek et al, 2005). 
In a recent study by Fornuskova et al (2010), association of COX subunits IV and Va to subunit I 
were shown to be necessary for further assembly of functional COX. Therefore, if COX IV is being 
knocked down, the amount of functional COX may well be greatly reduced (depending on the 
effectiveness of the RNAi construct). This decrease in COX would ultimately lead to the observed, 
severe phenotype in knockdown flies. 
 
COX subunit Vb is added to the respiratory chain complex at a later stage of assembly, in the 
formation of the assembly intermediate S3 (Nijtmans et al, 1998). The catalytic core of functional 
COX has already been established before joining subunit Vb to the complex. Therefore knocking 
down subunit Vb in flies should have less dramatic effects on phenotype than COX IV knockdown. 
However, Galati et al (2009) showed in their study that knocking down COX Vb in mammalian 
cells reduces the amount of COX subunits IV and Va. This result  is  contradictory to the result  of 
Glerum and Tzagoloff (1997), who showed that knocking down the yeast homolog of mammalian 
COX Vb in Saccaramyches cerevisiae caused very little decrease in the amount of COX subunits 
IV and Va. Thus it is yet unclear whether knocking down COX Vb affects the amount of COX IV 
in  mitochondria.  In  this  study,  the  effect  of  COX  Vb  knockdown  on  the  phenotype  of  D. 
melanogaster was milder than that produced by COX IV knockdown. Therefore, it can be presumed 
that COX Vb knockdown has a more modest effect on COX activity/assembly. 
 
Diaz et al (2006) showed that COX deficiency could also have an effect on levels of complex I. In 
their study, Cox10 knockout mouse fibroblasts had considerably decreased amounts of complex I 
present in mitochondria. In another mouse model, with supressed expression of COX IV, levels of 
complex I were also significantly decreased due to the resultant COX deficiency (Li et al, 2007). 
Taking into account these previous results, it is possible that complex I was also affected in the 
knockdown of COX in Drosophila. Owing that COX IV-KD was more efficient than COX Vb-KD, 
the level of complex I may well be lower in the COX IV-KD. This could have also influenced the 
phenotype of COX knockdown flies. However, in a study by Antonicka et al (2003), patients with 
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severely reduced COX activity caused by a Cox10 mutation, had normal levels of complex I and 
other respiratory complexes. In the nematode C. elegans, COX deficiency did not cause decrease in 
the levels of complex I, but a decrease in the activity of the complex (Suthammarak et  al, 2009). 
Thus, the role of COX in complex I assembly and stability is still unclear (Lazarou et al, 2009). It 
would have been interesting to see, how each COX subunit knockdown is affecting other 
respiratory chain complexes and supercomplex structure. This could be analysed using Blue Native 
polyacrylamide gel electrophoresis (BN-PAGE) (depicted in McKenzie et al, 2007). 
 
A much simpler explanation could be the cause of the difference in phenotype severity in the COX 
knockdown  flies.  The  level  of  knockdown  achieved  with  the  expression  of  an  RNAi  construct  is  
never 100 % (Shan, 2010). Therefore there is always residual expression and therefore synthesis of 
the  target  protein  left  within  the  knockdown  cells.  In  this  study,  RNAi  against  COX  IV  might  
simply be more efficient in directing CoIV-mRNA to degradation than RNAi against CoVb-mRNA. 
An attempt at quantifying the level of COX knockdown was performed by staining fixed sections of 
fly brain and muscle with COX specific antibodies, but interpreting the images turned out to be 
challenging. RT-qPCR is the preferred technique in quantifying mRNA levels in a given sample 
(Nolan et al, 2006), but in this case it was considered too laborious to extract nervous-tissue from 
flies for this type of analysis. 
 
6.2.2 Stronger knockdown phenotype in male flies could be an implication of dosage 
compensation or perhaps it is due to differences in female and male fly physiology 
 
Male flies were more affected by the knockdown than female flies according to the findings made 
in this study. A result that isn’t entirely suprising when you consider that female and male flies are 
very different on several levels. Sexual dimorphism has resulted in very different gene expression in 
males and females. In a study by Chang et  al (2011), he and his associates showed that there are 
more than 1 000 genes that differ in their  expression level,  and at  least  the same amount of genes 
that differ in their expressed isoforms, between female and male flies. This level of differing gene 
expression ultimately leads to differences between female and male physiology and behaviour. 
Different physiology between females and males can be due to different endocrine signalling. Males 
and females secrete hormones in varying amounts that will affect for example, the behaviour and 
growth of an individual. Hormonal signalling is mainly directed by nervous tissue, and in turn 
nervous tissue is very much affected by hormonal signalling. It has been shown that female and 
male central nervous systems respond differently to hormonal signals in rats (Cooke et  al, 1999) 
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and in Drosophila (Belgacem and Martin, 2006). Therefore, it is no surprise if females and males 
have different phenotypes in flies whose nervous system is subject to knockdown of COX. 
 
A phenomenon related to sexual dimorphism is dosage compensation of X chromosomal genes. 
Dosage compensation is a process by which X-chromosomal gene products are produced in equal 
amounts in organisms where gender is determined by the number of X chromosomes 
(Charlesworth, 1996). In Drosophila melanogaster, where male flies have one X chromosome and 
females have two, dosage compensation doubles the expression level of male X chromosomal genes 
(Baker et  al, 1994). In the case of X-chromosomal elav-GAL4 driven COX knockdown, the 
difference between the observed female and male phenotypes could be due to dosage compensation. 
More GAL4 is likely to have been expressed in males than in females, although both had just one 
copy  of  the  driver  gene.  GAL4  results  in  active  transcription  of  UAS-RNAi  genes.  With  more  
GAL4 present in male neurons, the male flies had a stronger knockdown phenotype than females. 
To test the hypothesis of whether dosage compensation leads to more RNAi in male flies, the 
expression level of COX subunits should be measured in both male and female flies with elav(X)-
GAL4 driver. 
 
Dosage compensation is unlikely to account for the difference in knockdown phenotype between 
male and female flies with elav(3)-GAL4 driven COX knockdown however. This driver is situated 
in chromosome 3 and therefore both sexes should produce GAL4 in equal amounts. The same 
pattern of difference between COX knockdown phenotypes in male and female flies has been 
observed in other studies as well (Ni et al, 2007). Ni and his colleagues proposed that a difference 
in  UAS-RNAi  expression  could  be  due  to  the  difference  in  the  developmental  time  of  male  and  
female flies. Because male flies take slightly more time to developed, they may well produce more 
RNAi hairpin molecules. However, UAS-RNAi expression is entirely dependent on the GAL4 
driver and therefore the difference in UAS-RNAi expression reflects differences in GAL4 
expression between male and female flies. The reason behind the difference in male and female 
phenotypes  cannot  completely  rule  out  dosage  compensation,  as  the  RNAi  constructs  contain  X  
chromosome derived elements (Ni et al, 2007). These elements could recruit proteins required for 
dosage compensation in male flies, even though the construct is not actually situated in X 
chromosome.  
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6.3 Addition of alternative respiratory chain components changes redox homeostasis in 
mitochondria of COX knockdown flies 
 
6.3.1 AOX alleviates respiratory chain deficiency related symptoms by restoring redox 
balance 
 
Alternative oxidase from the tunicate Ciona intestinalis has been designed to be expressed 
constitutively in human cells (Hakkaart et al, 2006) and conditionally in Drosophila melanogaster 
(Fernandez-Ayala et al, 2009). In a more recent study, AOX has been expressed in a whole mouse 
model (El-Khoury et al,  2013).  In  all  of  the  above  cases,  AOX  expression  does  not  have  any  
detrimental effects on the organism, and it stays inactive in mitochondria until the cytochrome 
component of the respiratory chain is blocked, or the redox state of the cell is highly reduced. In this 
study, AOX expression was able to rescue either partially, or fully, the phenotypes resulting from 
knockdown of COX subunit IV and Vb, respectively. In previous studies, AOX expression has been 
used to rescue other types of mitochondrial deficiency, including Parkinson’s disease phenotype 
induced by dj-1ȕ mutation in Drosophila (Fernandez-Ayala et al, 2009), dopaminergic cell loss in 
flies with knockdown of mitochondrial polymerase Ȗ catalytic subunit (Humphrey et al, 2012) and 
decreased cell respiration in Cox15 depleted human skin fibroblasts (Dassa et al, 2009a). 
 
In this study, AOX coexpression was not sufficient to make COX IV knockdown flies survive after 
the  eclosion.  It  would  seem  that  the  rescue  capability  of  AOX  is  tied  to  the  extent  of  COX  
dysfunction (Fernandez-Ayala et  al, 2009). AOX expression, driven in this study by elav-GAL4 
drivers, produced a complete rescue of COX Vb knockdown flies, this is suggestive of COX Vb 
knockdown having a lesser effect on levels and activity of COX than does COX IV knockdown. 
The alleviating effect of AOX in mitochondria with COX dysfunction is based on the fact that it can 
partially bypass the respiration chain and transfer electrons straight from reduced ubiquinol to 
oxygen (Humphrey et al, 2012). Subsequently it also relieves metabolic acidosis and diminishes 
ROS production in mitochondria (Rustin and Jacobs, 2009). The most significant advantage of 
AOX expression in a situation of decreased COX activity is its ability to revive ATP production, as 
electron  flow  and  subsequent  proton  pumping  are  allowed  to  continue  through  complex  I  of  the  
respiratory chain (El-Khoury et al, 2013). However, ATP production is not fully restored to initial 
levels,  as two of the three proton pumping enzymes are bypassed. In a case of AOX rescue, ATP 
production is restored to a level over the threshold that allows vital cellular functions to carry on. 
This is  likely to be the situation in COX Vb knockdown flies,  where AOX expression rescued all  
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detrimental phenotypes. In COX IV knockdown flies however, ATP production could not be 
restored above the required threshold, most likely because of a greater reduction in COX activity.  
 
This study and the previous studies show the capability of AOX to alleviate symptoms caused by 
mitochondrial (especially COX) dysfunction. Therefore it should be considered as a potential future 
therapeutic tool to compensate for these deficiencies in humans. It has already been expressed 
beneficially in human cells (Dassa et al, 2009a, 2009b) but there are still a lot of open questions to 
be answered about the enzyme function in physiological conditions before it can be applied to 
human therapeutics. 
 
6.3.2 Ndi1 expression exacerbates detrimental phenotypes by feeding additional electrons to 
the defective respiratory chain 
 
As mentioned before, Ndi1 is a protein composed of a single polypeptide chain that can transfer 
electrons from NADH to ubiquinone thus bypassing complex I of the respiratory chain (Cho et al, 
2012). Ndi1 expression has been previously shown to prolong life expectancy in flies (Bahadorani 
et al, 2010; Sanz et  al,  2010b) and also rescue flies with complex I  deficiency (Cho et  al, 2012). 
However, Ndi1 cannot rescue deleterious phenotypes resulting from other respiratory chain 
complex deficiencies (Humphrey et al, 2012). The inability of Ndi1 expression to rescue flies with 
complex  IV  deficiency  was  also  documented  in  this  study,  with  some  interesting  additional  
findings. Ndi1 coexpression made flies die even faster than when they were expressing a 
knockdown construct only. This could be due to the fact that Ndi1 bypasses complex I of the 
respiratory chain. The overall proton pumping activity of complex I is decreased when Ndi1 
transfers electrons from NADH to ubiquinone without any proton translocation. Thus the 
electrochemical gradient is lower and ATP production is decreased. The even lower ATP levels 
resulting from Ndi1 expression could cause the early death observed in COX knockdown flies. Sanz 
et al (2010a) showed that ROS production was decreased in aging flies that were expressing Ndi1. 
However, in this study the electrons fed by Ndi1 into the respiration chain possibly cause an 
increase in the production of reactive oxygen species, which will bring further damage to the 
mitochondria. This damage ultimately leads to the observed early death of Ndi1 expressing COX 
knockdown flies. 
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6.4 Experimental considerations and future prospects 
 
In addition to new experiments mentioned above (climbing and bang-sensitivity -assays and BN-
PAGE or RT-qPCR for quantification of COX knockdown) some of the experiments presented here 
could be validated by thorough repeats with some moderate changes in the experimental set-up. The 
lethality assays performed in this study show the number of flies that have eclosed from each cross. 
Comparison between the number of eclosed knockdown flies and wild-type flies is not the best way 
to evaluate the effect of knockdown on lethality, because it is affected by the overall number of 
eggs laid. Therefore it would be more informative if the number of eclosed flies would be presented 
as percentages of the number of eggs laid. In order to do so, either the number of eggs or pupae 
should be counted, depending on whether the knockdown induces lethality in early or late stage of 
development, respectively. The number of eggs or pupae could then be normalized using the 
respective number in wild-type vials. Another approach could be to normalize the number of 
eclosed  flies  by  transferring  a  specific  amount  of  eggs,  after  crossing,  into  fresh  fly  food  vials  
(Agrawal et al, 2005). 
 
Producing comparable data of the level of COX knockdown from paraffin sections of fly brain and 
muscle proved difficult using the methods shown above. In fact, sectioning of paraffin embedded 
fly tissues is a technique rarely used anymore. Most of the immunostaining is currently done on 
whole mount tissues. This eliminates many steps of the staining process and reduces the handling 
time of the tissue. It also gives a better view of the three dimensional structure of the tissue because 
it does not need to be sectioned. In future experiments, a whole mount immunostaining technique 
would be used. 
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7. CONCLUSIONS 
 
The first aim of this study was to characterize the phenotypes of neuron-specific knockdown of 
COX in Drosophila melanogaster. Out of the three different neuronal specific GAL4 drivers that 
were used to drive RNAi expression in flies, two were able to produce observable phenotypes. The 
severity of the phenotype seemed to be dependent on the COX subunit, which was being knocked 
down.  COX  IV-KD  produced  stronger  phenotype  than  COX  Vb-KD,  which  is  thought  to  reflect  
their different roles in COX biogenesis. COX IV is added to the enzyme complex earlier than COX 
Vb and depleting COX IV would thus be expected to cause more pronounced COX deficiency than 
COX Vb depletion. The effect of COX subunit knockdown on the integrity of mitochondrial 
supercomplexes or on the function of other respiratory chain complexes should be studied further. 
 
The second aim of the study was to test whether AOX expression is able to rescue the deleterious 
phenotypes. The experiments confirmed previous results in that AOX is able to partially or fully 
rescue phenotypes resulting from COX deficiency. Thus AOX shows its potential to functions as a 
potential therapeutic agent for COX dysfunction. However, a somewhat surprising result showed 
that  expressing  Ndi1  in  COX  deficient  flies  makes  the  phenotype  even  worse.  The  ability  of  
alternative respiratory enzymes to alleviate respiratory chain dysfunction logically reflects their 
ability to restore ATP production. I hypothesise that, in case of AOX expression in COX deficient 
neurons, proton pumping through complex I is facilitated, which restores ATP production over the 
threshold level that allows vital cellular pathways to stay active. In case of Ndi1 coexpression, 
electrons bypass complex I of the inhibited respiratory chain, which subsequently drops the level of 
ATP production even further, leading to the observed more severe phenotypes. 
 
This  study  was  also  able  to  show  the  permissive  expression  of  neuronal  GAL4  drivers.  A  more  
precise examination of the elav-GAL4 drivers expression pattern showed leaky expression in the 
muscle of pupal and adult stage flies. Therefore it cannot be concluded that the observed 
phenotypes were exclusively due to neuronal knockdown of COX. This also has implications for 
the interpretation of other experiments that utilize these GAL4 drivers. 
 
According to the results presented here and in previous studies, AOX should be considered as a 
potential  therapeutic  agent  for  patients  with  COX  deficiency.  However,  more  studies  on  the  
function of AOX in mammalian cells are still required. Also the development of safe and applicable 
vectors for gene therapy is not yet advanced and the use of AOX in the clinic is therefore still far in 
the future. 
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APPENDICES 
 
Appendix 1. 
 
Crossing  schemes  to  study  the  effects  of  COX subunit  knockdown on  viability  and  phenotype  of  
Drosophila melanogaster and the attempt to rescue deleterious phenotypes with AOX coexpression, 
and to characterize neural specific elav-GAL4 drivers expression pattern. 
A Following crosses were made to study the effects of COX subunit knockdown on development (lethality 
assay): 
i.  
ii. 
iii.  
B Following crosses were made to determine if AOX is able to rescue the detrimental effects of COX subunit 
knockdown on development (lethality assay): 
i. 
ii.  
C  The following crosses were set up to study the effect of COX subunit knockdown on survival: 
i.  
ii.  
iii.  
D To study if AOX expression is capable of rescuing decreased viability in Drosophila melanogaster, following 
crosses were set up: 
i. 
ii. 
E The following crosses were done to characterize neural specific elav-GAL4 drivers expression pattern: 
i.   
ii.  
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Appendix 2. 
 
Representative slides of H&E stained fly brain is presented in Figure A2.1. COX knockdown flies 
stuck in fly food and flies unable to eclose are presented in Figure A2.2. 
 
 
 
 
 
 
 
Appendix 3. 
 
Lethality assay was also performed on flies with COX subunit Vb knockdown and GFP expression 
driven by elav(X)-GAL4. GFP was expressed as a control for AOX. The test was repeated twice 
with same type of results (Figure A3). 
 
Figure A2.1. HE  stained  paraffin sections of COX subunit IV knockdown fly brain when knockdown is 
driven with elav(X)-GAL4. A) A representative slice of COX IV knockdown female brain.  B) A representative 
slice of wild-type female brain. 
Figure A2.2. Influence of COX IV knockdown on fly phenotype when knockdown is driven with elav(X)-
GAL4. A) COX IV;AOX flies all get stuck in the food and die soon after eclosion. B) COX IV knockdown flies 
cannot even eclose and die in the pupal case. 
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Appendix 4. 
 
Images of COX subunit knockdown in brain and muscle stained with antibodies are presented in 
Figure A4.1 and A4.2. Antibody against COX IV was used to stain COX in selected tissues, 
because it was proven functional by previous work (even though it is one of the subunits knocked 
down). 
 
Figure A3. Mean number of eclosed flies when COX subunit Vb knockdown and transgene expression is 
driven with elav(X)-GAL4. Females are expressing the transgene and RNAi, whereas male flies are not. Means are 
presented ± SD. 
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Figure A4.2. COX knockdown in the muscle tissue of 
Drosophila melanogaster. COX subunit knockdown is driven 
with elav(X)-GAL4. ATP5A is a control and should not be 
affected by the COX subunit knockdown. Scale bar 20 µm. 
Figure A4.1. COX knockdown in the central nervous system of 
Drosophila melanogaster. COX subunit knockdown is driven with 
elav(X)-GAL4. ATP synthase subunit 5 (ATP5A) is a control and 
should not be affected by the COX subunit knockdown. Scale bar 20 
µm. 
